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1. Low melting mixtures – the “greener” ionic liquids? 
 
 
There is pressing need to replace hazardous and harmful solvents with “green” or 
“sustainable” media. Natural compounds have recently been used to produce deep 
eutectic solvents, sugar melts, or ionic liquids. This review presents physicochemical 
data of these reaction media and highlights recent advances in their use in organic 
synthesis and biotransformations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C. Ruß, B. König, Green Chem., 2012, submitted. 
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Introduction 
What makes a solvent green? The prevalent opinion is that the ideal green solvent is 
safe for both the human beings and the environment and its use and manufacture are 
sustainable.1, 2 
Ionic liquids (ILs) are an intensively investigated class of alternative reaction media. 
They are defined as salts with a melting point below the boiling temperature of water 
(100 °C).3 From all of their exceptional properties like low flammability, stability 
against air and moisture, excellent solvation potential, low water content, chemical and 
thermal stability, high heat capacity, density and conductivity, their negligibly low 
vapour pressure is the most prominent feature why they are considered as green. 
However, one property still in question - their impact on the environment – is 
intensively discussed.4, 5 Ideally, the components of a green solvent expose a low acute 
toxicity and are rapidly degraded in the environment. The current consensus is that 
ionic liquids cannot be generalised as either green or toxic, but that their environmental 
impact is strongly dependent on the kind of cation and anion used to produce the IL.5 
For this reason, reaction media entirely composed of biomaterials have been developed 
which unite the outstanding physicochemical properties of ILs with the advantage of 
biodegradable and non-toxic starting materials. Additional advantages over ILs are 
their facile preparation and the use of readily available and inexpensive starting 
materials. 
This review will focus on the application of these solvents made from renewable 
resources in organic syntheses. Some examples of biotransformations will be portrayed 
and also the physicochemical properties will be highlighted. As this is a fast growing 
and widespread field, we are not trying to be comprehensive, but try to give a general 
trend of this research area.  
Classification of low melting mixtures and their synthesis 
A central role in the class of “bio-based” solvents plays 
(2-hydroxyethyl)trimethylammonium chloride, or simply choline chloride (ChCl). The 
quaternary ammonium salt choline is considered as a member of vitamin B family, 
supports a multitude of metabolic processes, and serves as a dietary supplement of 
 
1. Low melting mixtures – the “greener” ionic liquids? 
 5 
animal feeds.6 It is commercially produced by a simple gas phase reaction between 
trimethylamine, ethyleneoxide, and HCl.6  
The foundation for solvents based on renewable resources was laid in 2003 when 
Abbott et al. reported on low melting mixtures of urea and ChCl which are liquid at 
room temperature, terming them “deep eutectic solvents” (DES).7 A DES is defined as a 
mixture of hydrogen bond donor (HBD) systems with simple halide salts which 
produce liquids.8 Their physicochemical properties resemble those of ionic liquids. 
Abbott’s fundamental work inspired other researchers to exploit the unusual 
properties of this system. In the last years, different (uncharged) hydrogen bond 
donors of natural and synthetic origin were used in combination with choline 
chloride.8-12 As in the case of ILs, the melting point of the mixtures is not predictable, 
but some general trends can be derived. Abbott hypothesised that the melting point 
depression is caused by charge delocalisation due to hydrogen bonding between the 
halide anion and the hydrogen bond donor.7 In ionic liquids, the melting point is 
dependent on the charge distribution in the ions: the melting points tend to be lower 
when the charge is strongly delocalised or when the cations and / or anions are 
asymmetrical.3 A similar effect was observed for melts with quaternary ammonium 
salts: with increasing asymmetry of the cation, the melting point decreases.7 
Furthermore, the freezing points are influenced by the hydrogen bond strength of the 
different negatively charged counterions of the choline salts in urea mixtures.7 The 
preparation of deep eutectic solvents is very simple: the mixed components are stirred 
under heating (~ 80 °C) until a homogeneous, clear liquid has been formed.8, 12  
The exchange of the halide anion for organic anions like carboxylates was a recent 
advancement to obtain ionic liquids based completely on biomaterials. This concept 
was firstly introduced by Nockemann et al. in 2007.13 They synthesised ionic liquids by 
a metathesis reaction of choline chloride and the sodium salts of the non-nutritive 
artificial sweeteners acesulfame and saccharin, followed by purification using ion-
exchange chromatography. Also in 2007, Fukaya et al. developed room temperature 
ionic liquids composed of biomaterials, and termed them “bio ionic liquids”.14 These 
so-called “bio-ILs” were prepared by two-step anion exchange reactions of choline 
hydroxide with different carboxylates. Simple alkanoic acids were used as counterions 
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by Petkovic et al. in 2009.15 They prepared ionic liquids by titration of cholinium 
hydrogen carbonate with the corresponding acid. Recently, Liu et al. introduced room 
temperature ionic liquids using amino acids as anions and choline as cation.16 They 
also used choline hydroxide as starting material which was added dropwise to an 
aqueous solution of eighteen different amino acids.  
Sugar melts, low melting eutectic mixtures of sugar, urea, and salt, were described by 
Imperato et al.17-19 The stable melts, which consist merely of neutral components, are 
prepared by heating up the grinded compounds until a clear liquid has formed. The 
obtained eutectic mixtures exhibit melting points above 60 °C. Even simpler eutectic 
mixtures termed “natural deep eutectic solvents” (NADES) were published by Choi et 
al. in 2011.20 They presented 30 defined combinations of ChCl, organic acids, amino 
acids and sugars giving viscous liquids at room temperature. These media might play 
a role as water-free natural ionic liquids in cells, e.g. for dissolving metabolites or as 
solvent for biochemical reactions.  
A) Overview of the physicochemical properties 
1.1 Used components and melting points  
Similar to ILs, the melting points of eutectic mixtures are not yet predictable. The 
liquid character of the salt mixtures is attributed to a reduction of Coulomb forces. 
They decrease with a large volume (or buried charge) and asymmetric charge 
distribution of the molecular ions. The melting points (Tm), freezing points (Tf) or glass 
transition temperatures (Tg) are summarised below (Table 1-9). In those cases, when 
two different melting points were determined, both values are given. Interestingly, the 
melting points of DES and ILs made from the same components, e.g. benzoic acid 
(Table 1, entry 3) and benzoate (Table 7, entry 17) or tartaric acid (Table 2, entry 4) and 
H-tartrate (Table 7, entry 16) deviate strongly from each other; mostly, the melting 
points of the DESs are lower than the melting points of the ILs. 
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1.1.1 Deep eutectic solvents based on choline chloride 
 
 
 
 
 
Table 1 Deep eutectic solvents based on choline chloride (ChCl) and monocarboxylic acids. 
HBD: hydrogen bond donor, ChCl : HBD ratio in (mol:mol). 
Entry Compound Structure 
ChCl : HBD 
ratio  
T (°C) Ref.
1 Valeric acid 
 
1:2 Tf 22 21 
2 Levulinic acid 
 
1:2 Tm 
Liquid at 
rt 
12 
3 Benzoic acid 
 
1:2 Tf 95 9 
4 Phenylacetic acid 
 
1:2 Tf 25 9 
5 Mandelic acid 
 
1:2 Tf 33 21 
6 
4-Hydroxybenzoic 
acid  
2:1 
1:2 
Tm 
Tf 
87 
97 
12 
21 
7 Gallic acid 
 
2:1 Tm 77 12 
8 trans-Cinnamic acid 
 
1:1 
Tm 
Tf 
93 
101 
12 
21 
9 p-Coumaric acid 2:1 Tm 67 12 
10 Caffeic acid 2:1 Tm 67 12 
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Table 2 Deep eutectic solvents based on choline chloride and dicarboxylic acids. 
HBD: hydrogen bond donor, ChCl : HBD ratio in (mol:mol). 
Entry Compound Structure ChCl : HBD ratio T (°C) Ref. 
1 Oxalic acid 
 
1:1 Tf 34 9 
2 Malonic acid 
 
1:1 Tf 10 9 
3 Glutamic acid 
 
1:2 Tf 13 21 
4 L-(+) Tartaric acid 
 
2:1 Tm 47 12 
5 Itaconic acid 
 
1:1 
2:1 
Tm 57 12 
6 Succinic acid 
 
1:1 Tf 71 9 
7 Adipic acid 
 
1:1 Tf 85 9 
8 Suberic acid 1:1 Tm 93 12 
 
 
 
Table 3 Deep eutectic solvents based on choline chloride and tricarboxylic acids. 
HBD: hydrogen bond donor, ChCl : HBD ratio in (mol:mol). 
Entry Compound Structure ChCl : HBD ratio Tf (°C) Ref. 
1 Citric acid 
 
2:1 69 9 
2 Tricarballylic acid O
HO
O OH
O
OH
2:1 90 9 
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Table 4 Deep eutectic solvents based on choline chloride and alcohols. 
HBD: hydrogen bond donor, ChCl : HBD ratio in (mol:mol). 
Entry Compound Structure ChCl : HBD ratio T (°C) Ref.
1 Glycerol  1:2 Tf -40 
8 
2 Ethylene glycol  1:2 Tf -20 21 
3 Mannitol 1:1 Tf 108 21 
4 D-Fructose 
 
1:2 Tf 5 21 
5 D-Glucose OHO
HO
OH
OH
OH  
1:2 Tf 14 21 
6 Vanilline 
 
1:2 Tf 17 21 
7 Xylitol 
 
1:1 Tm Liquid at rt 12 
8 D-Sorbitol 1:1 Tm Liquid at rt 12 
9 D-Isosorbide 
 
1:2 Tm Liquid at rt 12 
 
 
 
Table 5 Deep eutectic solvents based on choline chloride and urea derivatives. 
HBD: hydrogen bond donor, ChCl : HBD ratio in (mol:mol). 
Entry Compound Structure ChCl : HBD ratio Tf (°C) Ref.
1 Urea 
 
1:2 12 7 
2 1,3-Dimethylurea (DMU)
 
1:2 70 7 
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Table 6 Other natural ammonium salts used in eutectic mixtures. 
Entry Ammonium salt (AS) Structure HBD Ratio (AS:HBD) Tm Ref. 
1 L-Carnitine Urea 2:3 (wt:wt) 74 22 
2 Betaine hydrochloride 
 
Urea 15:85 (mol:mol) 27 23 
3 Betaine hydrochloride 
 
Glycerol  rt 24 
 
1.1.2 Ionic liquids using choline as cation and natural products as counterions 
Table 7 Ionic liquids based on the cholinium cation and carboxylates (entry 1-17) and artificial 
sweeteners (entry 18 and 19). Expectedly, the molar ratio of anion to cation is 1:1. 
a n. d. not detected 
Entry Compound Structure Tm (°C) Tg (°C) Ref. 
1 Acetate 
 
51 
80 
n. d. a 
n. d. a 
14 
15 
2 Propionate 
 
n. d.a -74 14, 15 
3 Butanoate 
 
45  15 
4 Valeric acid 
 
31  15 
5 Hexanoate 
 
52  15 
6 Octanoate 
 
26  15 
7 Decanoate 50  15 
8 Isobutyrate 
 
35  15 
9 Pivalate 
 
57  15 
10 Glycolate 
 
38 -67 14 
11 Tiglate 
 
n. d.a -62 14 
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12 H-Succinate 
O
HO
O
O-
 
n. d.a -52 14 
13 H-Maleate 
 
25 -72 14 
14 H-Fumarate 
 
80 n. d. a 14 
15 H-Malate 
 
99 -40 14 
16 H-Tartrate 
OH
OH O
O-
O
HO
 
131 -6 14 
17 Benzoate 
 
47 -51 14 
18 Acesulfamate
 
69 n. d. a 13 
19 Saccharinate 
 
25 n. d. a 13 
 
 
Table 8 Ionic liquids based on the cholinium cation and amino acids as counterions (molar 
ratio 1:1). 
Entry Counterion Tg (°C) Ref.  Entry Counterion Tg (°C) Ref.
1 Glycine -61 16 empty 10 Tryptophane -12 16 
2 Alanine -56 16  11 Proline -44 16 
3 Serine -55 16  12 Aspartic acid -22 16 
4 Threonine -39 16  13 Glutamic acid -18 16 
5 Valine -74 16  14 Asparagine -14 16 
6 Leucine -47 16  15 Glutamine -40 16 
7 Isoleucine -47 16  16 Lysine -48 16 
8 Methionine -61 16  17 Histidine -40 16 
9 Phenylalanine -60 16  18 Arginine -10 16 
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1.1.3 Low melting sugar mixtures 
Table 9 Melting points and composition of low melting sugar mixtures.  
DMU: 1,3-dimethylurea; sugar: urea : salt ratio (weight %). 
Entry  Carbohydrate Structure Urea Salt Ratioa  Tm Ref.
1 Citric acid 
 
DMU - 40:60 65 18 
2 Sorbitol 
 
DMU NH4Cl 70:20:10 67 18 
3 Maltose 
 
DMU NH4Cl 50:40:10 84 18 
4 Mannitol 
 
DMU NH4Cl 50:40:10 89 18 
5 Lactose DMU NH4Cl 50:40:10 88 18 
6 Mannose 
 
DMU - 30:70 75 18 
7 Fructose O
HO
OH
OH
OH
OH
 
DMU - 40:60 80 18 
8 Fructose O
HO
OH
OH
OH
OH
 
Urea NaCl 70:20:10 73 18 
9 Fructose 
 
Urea - 40:60 65 17 
10 Glucose 
 
Urea NaCl 60:30:10 78 18 
11 Glucose OHO
HO
OH
OH
OH  
Urea CaCl2 50:40:10 75 17 
12 Glucose OHO
HO
OH
OH
OH  
- 50:50 75 25 
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13 Galactose 
 
Urea NH4Cl 30:70:10 80 25 
14 
N-Acetyl-D-
glucosamin 
 
Urea NH4Cl 30:70:10 80 25 
15 L-Rhamnose 
 
Urea NH4Cl 30:70:10 80 25 
16 
2-Deoxy- D-
glucose  
Urea NH4Cl 30:70:10 80 25 
1.2 Polarity 
Solvent polarity is an important factor in chemistry as it can significantly influence the 
course of the reaction.26 Different scales exist to estimate the polarity of a solvent. One 
of the most commonly used empirical polarity scales is the ET(30) scale, introduced by 
Reichardt.27 The polarity is calculated from the wavelength (nm) of maximum 
absorbance of the standard solvatochromic betaine dye no. 30 (Reichardt’s dye) in 
solvents of different polarity at room temperature (25 °C) and normal pressure (1 bar) 
using the eqn. (1). As ET(30) is rather sensitive to hydrogen bonding solvents, Nile red 
or ET(33) are used instead.27 Nile red data is here reported as ET(NR), calculated from 
eqn. (2). 
ET(30) / kcal mol-1 = hcνmaxNA = 28 591 / λmax, 30 (1) 
 
ET(NR) / kcal mol-1 = hcνmaxNA = 28 591 / λmax , NR (2) 
 
(h= Planck’s constant, c= speed of light,  
νmax= wave number of absorption maximum, 
 NA= Avogadro’s constant) 
 
A normalised scale ( NTE ) was introduced to obtain dimensionless values, using water 
( NTE = 1.00) and tetramethylsilane (
N
TE = 0.00) as reference solvents, resulting in eqn. (3). 
)]()([
)]()([
TMSEwaterE
TMSEsolventEE
TT
TTN
T
−
−
=  (3) 
Table 10 summarises ET(30), NTE , and ET(NR) values of some common molecular 
solvents, ILs, sugar melts, and DES. 
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Table 10 Overview of determined ET(30), NTE , and ET(NR) (for the dye Nile Red) values of some 
common molecular solvents, ILs, sugar melts, and DES.  
[Emim]: 1-Ethyl-3-methylimidazolium, [Bmim]: 1-butyl-3-methylimidazolium. 
Solvent ET(30)/kcal mol-1  NTE  ET(NR) Ref. 
Water 63.1 1.000 48.21 18, 27 
Glycerol 57.0 0.812 - 27 
Ethylene glycol 
 
56.1 
56.3 
0.784
0.790
50.6 
- 
18 
27 
Ethanol 51.9 0.654 - 27 
2-Propanol 
 
48.5 
48.4 
0.549
0.546
52.94 
- 
18 
27 
Dimethylsulfoxide 
 
45.0 
45.1 
0.441
0.444
52.07 
- 
18 
27 
Dimethylformamide 
 
43.6 
43.2 
0.398
0.386
52.84 
- 
18 
27 
[Bmim][acetate] 50.5 0.611 - 28 
[Bmim][propionate] 49.1 0.568 - 28 
[Bmim][H-maleate] 47.6 0.522 - 28 
Citric acid-DMU  70.8 1.238 49.72 18 
Sorbitol-DMU-NH4Cl  68.1 1.154 50.16 18 
Maltose-DMU-NH4Cl  67.8 1.145 50.60 18 
Fructose-urea-NaCl  66.5 1.105 52.55 18 
Mannitol-DMU-NH4Cl 65.8 1.083 52.94 18 
Glucose-urea-NaCl 64.4 1.040 50.78 18 
Lactose-DMU-NH4Cl  53.9 0.716 52.55 18 
Mannose-DMU  53.9 0.716 51.79 18 
Carnitine-urea  - - 49.89 22 
Glycerol-ChCl  
 
58.58 
- 
0.86
0.84 
- 
8 
29 
Ethylene glycol-ChCl - 0.80 - 29 
Urea-ChCl - 0.84 - 29 
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The polarities of the sugar melts (ET(NR) = 50-52) and the DES ( NTE  =  0.80-0.86) are 
comparable to those of short chain alcohols (e.g. ethylene glycol, 2-propanol) and other 
polar, aprotic solvents (e.g. DMSO, DMF) (ET(NR) = 51-53 kcal mol-1, NTE  = 0.39-0.81)., 
and follow a similar trend as common ionic liquids.30 
1.3 Viscosity 
Viscosity describes the internal friction of a moving fluid or, in other words, the 
resistance of a substance to flow. Usually, the dynamic viscosity η for ILs are reported 
in centipoise (cP) which corresponds to milli pascal-second (mPa s) in SI units. While 
viscosities of ILs range from around 10 cP to values beyond 500 cP,3 the viscosities of 
the low melting mixtures shown in Table 11, range from 50 to 5000 cP for the mixtures 
of choline chloride with carboxylic acids,9 from 650 to 8500 cP for the ionic liquids of 
choline with carboxylates,14 and from 121 to 5640 cP for choline-amino acid liquids and 
are higher than those of ILs.16 In comparison with the viscosities of different common 
solvents like dichloromethane (0.413 cP), DMSO (1.987 cP), ethylene glycol (16.1 cP), 
and glycerol (934 cP), the viscosity of low melting mixtures is up to three orders of 
magnitude higher. Viscosity has a remarkable influence on the course of a chemical 
reaction: high viscosities can decrease the reaction rate in case of diffusion-controlled 
chemical reactions. In engineering, low viscosities are preferred as operational costs for 
e.g. stirring, mixing, and pumping can be reduced in practice.  
 
All listed low melting mixtures display rather high viscosities. As in ionic liquids, the 
viscosity in the low melting mixtures increases with increasing size or molecular 
weight of the anion. Furthermore, strong intermolecular interactions promote high 
viscosities. 
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Table 11 Viscosities of some common organic solvents, regular ionic liquids, “bio ILs”, and 
sugar-urea-melts. Ionic species are enclosed in brackets; amino acids were abbreviated using the 
three letter code. [Ch]: choline, [Emim]: 1-Ethyl-3-methylimidazolium, [Bmim]: 1-butyl-3-
methylimidazolium, [BMmorf]: 4-benzyl-4-methylmorpholinium. 
Solvent η (cP) at rt Ref.
CH2Cl2 0.413 31 
MeOH 0.544 31 
Water 0.890 31 
DMSO 1.987 31 
Ethylene glycol 16.1 31 
Glycerol 934 31 
[Ch][maleate] 650 14 
[BMmorf][maleate] 11.54 32 
[Emim] [maleate] 383 14 
[Ch][saccharinate] 328 (at 70 °C) 13 
[Ch][acesulfamate] 1072 13 
[Ch][glu] 2308 16 
[Bmim][glu] 83 33 
[Ch][gly] 121 16 
[Bmim][gly] 67 33 
[Emim][gly] 61 34 
[Ch][ser] 402 16 
[Emim][ser] 411 34 
[Ch][pro] 500 16 
[Emim][pro] 426 34 
Fructose-DMU  35.3 35 
Citric acid-DMU 289.6 35 
Maltose-DMU-NH4Cl 1732.7 35 
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1.4 Density 
Typical values for the density of ILs range from 1.12 to 2.4 g cm-1 and are therefore 
higher than those of organic solvents and water.3 The values of ILs are comparable to 
the densities of choline based ionic liquids and deep eutectic solvents (Table 12). 
1.5 Molar heat capacities and conductivity 
Molar heat capacities Cp of DESs are important to assess their potential for heat transfer 
applications. They were measured for pure choline chloride melts with urea, ethylene 
glycol and glycerol in the temperature range from 303.2 to 353.2 K and were 
determined to be between 181 and 254 J mol-1 K-1.38 Furthermore, Cp values increase 
with increasing temperature and increasing mole fraction of DES. Similar behaviour 
has previously been observed for other ionic liquids.39  
High conductivities, shown in Table 13, were observed in DES (comparable to ionic 
liquids)40, 41 and DES are therefore a highly investigated medium for electrochemical 
applications.42-59  
 
 
 
 
 
Table 12 Densities of different choline based DES and ILs. 
Solvent Molar ratio Density ρ [g cm-3] Ref. 
[Ch][propionate] 1:1 1.23 36 
[Ch][tiglate] 1:1 1.23 36 
[Ch][H-maleate] 1:1 1.38 36 
[Ch][saccharinate] 1:1 1.383 13 
[Ch][acesulfamate] 1:1 1.284 13 
ChCl-urea  1:2 1.25 10, 37 
ChCl-ethylene glycol 1:2 1.12 37 
ChCl-glycerol 1:2 1.18 37 
ChCl-malonic acid 1:1 1.25 37 
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Table 13 Conductivity of some DES and ILs 
Solvent system Conductivity σ (mS cm-1) Ref.
ChCl-carboxylic acids 0.1 to 10 9 
ChCl-urea  0.199 10 
ChCl-ethylenglycol 7.61 11 
ChCl-glycerol 1.047 11 
[Ch][saccharinate] 0.21 13 
[Ch][acesulfamate] 0.45 13 
 
B) Reactions in low melting mixtures 
Deep eutectic solvents and sweet eutectic mixtures are an environmentally benign 
alternative to hazardous (organic) solvents and might replace them in part. Their 
application in organic synthesis has notable advantages. As most of the components 
are soluble in water, addition of water to the reaction mixture dissolves the reaction 
medium. The organic products either form a separate layer or precipitate and can be 
filtered off. Furthermore, solvent and catalyst may be reused for another reaction cycle. 
2.1 Reactions in DES 
A variety of organic reactions were performed in deep eutectics solvents, mainly 
focused on the choline chloride-urea (1:2) eutectic mixture (Figure 1).  
In 2010, high yields and high purities were reported for the bromination of 
1-aminoanthra-9,10-quinone with molecular bromine in short reaction times.60 
Moreover, the reaction time and temperature of the Perkin reaction can be remarkably 
reduced without the use of a catalyst, while simultaneously improving the yields.61 
Coumarins were synthesized via a Knoevenagel condensation in short reaction times 
and high yields starting from salicyl aldehydes and active methylene compounds.62 
Recently, it was shown that the reduction of epoxides and carbonyl compounds with 
sodium borohydride can be conducted regio- and chemoselectively in good to excellent 
yields.63  
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2.2 Reactions in low melting (carbohydrate) mixtures 
“Sweet” low melting mixtures based on simple sugars or sugar alcohols and urea 
(derivatives) were introduced as reaction media for a variety of organic C-C-coupling 
reactions (Figure 2). The Diels-Alder reaction of cyclopentadiene with methyl acrylate 
was performed in high yields and endo/exo ratios comparable to those using ionic 
liquids and scCO2.17, 64 Metal-catalysed reactions like Suzuki,18, 22 Heck,22 and 
Sonogashira reaction,22 and the Huisgen 1,3-dipolar cycloaddition22 were also 
successfully conducted in high yields. By exchanging the sugar melts by a carnitine-
urea melt, reduced yields in the Heck reaction, a lower endo/exo ratio in the Diels-Alder 
reaction, but similar yields in the Huisgen 1,3-dipolar cycloaddition were observed.22 
Although the melts consist of chiral components, no asymmetric induction was 
observed in the catalytic hydrogenation of acetamido α-cinnamate.18 Quinazoline 
Bromination60 
 
Perkin reaction61 
 
Knoevenagel condensation62 
 
Reduction of epoxides and carbonyl compounds63 
 
Figure 1 Some organic reactions in DES (Choline chloride (ChCl)-urea mixtures). 
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derivatives were synthesised in high yields via a one-pot three-component coupling 
reaction of 2-aminoaryl ketones, aldehydes, and ammonium acetate using maltose-
DMU-NH4Cl.65  
The use of the sweet solutions is still limited due to their relatively high melting points. 
Another drawback of the melts is that their components are not chemically inert. 
However, a virtue can be made out of necessity. The reactivity of the sugars was 
utilised to convert efficiently carbohydrates into different glycosyl ureas.25 
Furthermore, 5-hydroxymethylfurfural, an important organic intermediate, was 
produced in such melts,66, 67 as well as the glucosylated derivative 5-(α-D-
glucosyloxymethyl)furfural (not shown below).68 
Inspired by these investigations, low melting mixtures of L-(+)-tartaric acid and urea 
derivatives were used to synthesise racemic dihydropyrimidinones via a Biginelli 
reaction. Remarkably, the melt fulfils the triple role of being solvent, catalyst, and 
reactant.69  
 
Diels-Alder17, 22  
 
 
Suzuki coupling18 
 
 
Heck reaction22 
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Sonogashira reaction22 
R
Br
+
mannose-DMU
2 mol% PdCl2(PPh3)2
iPrNH (3.6 eq)
80 °C, 2 h
61 - 79 %
R Ph
R = H, NO2  
Huisgen 1,3 dipolar reaction22 
 
Catalytic hydrogenation18 
 
Synthesis of glycosylureas25 
 
Catalyst free quinazoline multicomponent synthesis65 
 
Biginelli reaction69 
 
Figure 2 Organic reactions in low melting carbohydrate mixtures. 
a Carbohydrate melts used as reaction media: fructose-DMU (70:30), maltose-DMU-
NH4Cl (50:40:10), lactose-DMU-NH4Cl (60:30:10), mannitol-DMU-NH4Cl (50:40:10), 
glucose-urea-CaCl2 (50:40:10), sorbitol-DMU-NH4Cl (70:20:10), citric acid-DMU (40:60).  
b Carbohydrate melts used as solvent: fructose-urea-NaCl (70:20:10), maltose-DMU-
NH4Cl (50:40:10), mannose-DMU (30:70), lactose-DMU-NH4Cl (60:30:10), mannitol-
DMU-NH4Cl (5:4:1), sorbitol-DMU-NH4Cl (7:2:1), glucose-urea-NH4Cl (6:3:1). 
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2.3 Biocatalytic reactions 
Enzymes catalyse a broad spectrum of organic reactions like hydrolyses, oxidations, 
reductions, addition-elimination reactions, halogenations etc. chemo-, regio- and 
enantioselectively.70 Their natural medium is water. However, hydrophobic reactants 
and products are sparely soluble in water. Although enzymes display the highest 
catalytic activity in water, the biocatalysts can work in non-aqueous media, such as 
organic solvents or ionic liquids. The most prominent advantage of non-aqueous 
media is that thermodynamic equilibria can be shifted from hydrolysis to synthesis. 
Accordingly, hydrolases can be used to form ester or amide bonds. Furthermore, side 
reactions, like hydrolysis or protein degradation, which often occur in aqueous 
solutions, might be suppressed in non-aqueous media. ILs have been applied as non-
aqueous media in biotransformations and the field has recently been summarised by 
several reviews.71-73 Enzymes generally show comparable or higher activities in ionic 
liquids than in conventional organic solvents and in some cases, they also exhibit 
enhanced thermal and operational stabilities and give higher regio- or 
enantioselectivities.72 It is believed that enzymes can retain a residual hydration shell in 
non-polar solvents which stabilises the native fold.74  
Due to their similar physicochemical properties, it was thus evident to investigate deep 
eutectic solvents as reaction media for biotransformations. Gorke et al. was the first to 
use enzymes in DES and to assess the activity of different hydrolases in choline 
chloride-urea mixtures.29 Despite high concentrations of urea, which is a strong 
hydrogen bond donor and denatures proteins, and the presence of halides, which 
might inactivate or inhibit the proteins, the enzymes showed good catalytic activity. 
Furthermore, the conversion of styrene oxide to the corresponding diol with epoxide 
hydrolase was 20-fold enhanced using choline chloride-urea as co-solvent (Figure 3).29 
The hydrolysis of epoxides has been studied in more detail by Lindberg et al.75 They 
investigated the effect of different DES (1:2 mixture of ChCl with urea, ethylene glycol, 
or glycerol) as co-solvents on the hydrolysis of chiral (1,2)-trans-2-methylstyrene oxide 
enantiomers by potato EH StEH1 hydrolase. By applying DES as co-solvents, higher 
reactant concentrations could be achieved and the regioselectivity could be influenced. 
Zhao et al. studied the protease-catalysed transesterification activities in choline 
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chloride-glycerol mixtures (1:2).76 N-Acetyl-1-phenylalanine propyl ester was produced 
from the corresponding ethyl ester in 1-propanol with 98% selectivity and this reaction 
was favoured over the hydrolysis to the carboxylic acid. The same group developed a 
new species of eutectic mixture, a combination of the ionic liquid choline acetate with 
glycerol as hydrogen bond donor, thus achieving a lower viscosity.77 Candida antarctica 
lipase B catalysed highly selectively (>99%) the transesterification of ethyl sorbate with 
1-propanol in DES, as well as the transesterification of a mixture of triglycerides with 
methanol to biodiesel.  
The combination of DES and the enzyme lipase from Rhizopus oryzae as biocatalyst was 
used to synthesise (racemic) dihydropyrimidines by a Biginelli reaction (Figure 3).78  
Epoxide hydrolysis29 
 
Biginelli in DES with lipase78 
 
Figure 3 Some biotransformations in DES. 
2.4 Other applications 
ILs can even dissolve a wide variety of molecules and materials of low solubility. 
Different deep eutectic solvents (ChCl-urea, ChCl-malonic acid) increase the solubility 
of poorly soluble compounds (e.g. benzoic acid, griseofulvin, danazol, itraconazol) 5- to 
20 000-fold compared to their solubility in water.79 In NADES, an enhanced solubility 
of the flavonoid rutin, which is only slightly soluble in water, was observed.20 The 
solubility was 50- to 100-fold higher in glucose/fructose or aconitic acid/ChCl mixtures 
than in water.20 
Deep eutectic solvents are also versatile tools for the synthesis of inorganic materials 
and play a structure directing role as templates for the framework formation of metal 
phosphates,80 oxalatophosphates,81 aluminophosphates,82 carboxymethyl-
phosphonates,83 oxalatophosphonates,84 polyoxometalate-based hybrids,85 zeolites,86 or 
metal-organic frameworks.87 Their structure directing role was also observed for 
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nucleic acids which can form several secondary structures that reversibly denature on 
heating in a water-free DES. Four distinct nucleic acid structures can exist in DESs or 
room-temperature ILs.88 
Furthermore, monodispersed concave tetrahexahedral Pt nanocrystals were prepared 
by electrochemical shape-controlled synthesis in deep eutectic solvents44. Using this 
new synthetic method, the size and shape of the nanocrystals can be controlled without 
addition of seeds, surfactants, or other chemicals.   
In addition, ionic liquids derived from choline were also used to dissolve biopolymers. 
Choline acetate was reported to dissolve approx. 2-6 wt% of microcrystalline cellulose 
within 5-10 min at 110 °C.89 In another example, high solubilities of lignin and xylan 
were observed in liquids produced from choline and amino acids; they were also used 
for the selective extraction of lignin from lignocellulose.16 Cholinium alkanoates were 
shown to efficiently and specifically dissolve suberin domains from cork 
biopolymers.90 
 
Conclusion and Outlook 
The application and characterisation of low melting mixtures, i. e. deep eutectic 
solvents, sugar-urea-salt mixtures, and ionic liquids from biomaterials, are still in the 
early stage of development. Since the first publication on DES in 2003, the number of 
related articles has been growing nearly exponentially. Even while writing this review, 
new articles on the physicochemical properties of these alternative media, their 
application in synthesis, electrochemistry, or the structure directing role of 
biopolymers have been published, underpinning their importance and great potential. 
Basically, their properties and the fields of application overlap with those of regular 
ionic liquids. Their apparent advantage over ionic liquids, however is their easy access 
from inexpensive, non-toxic and completely biodegradable and biocompatible 
materials.15 Considering the variety of anions and cations nature provides, an 
enormous range of combinations could be synthesised to produce environmentally 
benign solvents, with tailor-made of properties. 
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2. Efficient preparation of β–D-glucosyl and β–D-mannosyl 
ureas and other N-glucosides in carbohydrate melts 
 
 
Sugar melts or solvent-free systems have been used to react simple unprotected 
hexoses at the C-1 atom with urea and urea derivatives to sugar-ureides by acid 
catalysis in short reaction times. In one step, β-D-glucosyl- and β-D-mannosyl urea 2a/b 
were obtained in high yields. D-Galactose 6, N-acetyl-D-glucosamine 7, L-rhamnose 8, 
and 2-deoxy-D-glucose 9 were converted likewise to the glycosyl ureas. Additionally, 
urea-related nucleophiles were investigated as melt components. N,N’-Ethylene 
urea 15, N,N’-allylurea 16 and ethyl carbamate 18 were β-selectively converted with 
D-glucose in good yields giving the corresponding N-glycosides. Under these 
conditions, however, the condensation product with N-octylurea 17 was not accessible. 
 
 
 
 
 
 
 
 
C. Ruß, F. Ilgen, C. Reil, C. Luff, A. Haji Begli, B. König  
“Efficient preparation of β-D-glucosyl and β-D-mannosyl ureas and other N-glucosides 
in carbohydrate melts” Green Chem., 2011, 13, 156-161 
 
C. Ruß optimised and extended the application of urea addition which was discovered 
by F. Ilgen and C. Reil. C. Luff performed the experiments under the supervision of 
C. Ruß regarding N,N'-allyl urea as project within her final thesis for her studies as a 
teacher. 
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Introduction  
In the 21st century, the utilization of renewable raw material will gain significant 
importance in the industrial conversion of chemicals. This fact is a consequence of 
diminishing fossil fuel reserves which will urge to develop new methodologies to 
make use of sustainable sources for chemical production in the near future.91 Since 
biomass is renewable, abundant and distributed widely in nature, it is a promising 
alternative for the sustainable supply of valuable intermediates and platform chemicals 
to the chemical industry.92  
Carbohydrates form the main part of biomass with more than 75 wt%.93 They can be 
used directly for chemical conversion or after hydrolysis of poly- and oligosaccharides 
to monosaccharides like D-glucose and D-fructose. Substitution at the most oxidized 
site in monosaccharides, the anomeric centre, gives access to the important and 
prominent group of the glycosides. O-,94 S-,95 C-96, 97 and N-glycosides98 are examples for 
this group of C-1 substituted monosaccharides. A representative of the N-glycosides is 
the stable class of glycosyl ureas. Glycosyl ureas are widely used in a mixture with 
phenol and water as an adhesive with excellent properties. This formulation is 
important for the forest product industry which is interested in reducing the phenol 
content in adhesives for construction material and furniture due to the toxicity of 
phenol.99 Glycosyl thymines can be prepared from glycosyl ureas as described by Sano 
et al.100 Another important application of glycosyl ureas is the use as lyophilization 
stabilizers for enzymes.101 Recently, Shoji et al. introduced a glycosyl urea based lectin 
adsorbent with high and controllable adsorption capacity, which can be manufactured 
conveniently.102 Structurally similar N-acyl-N’-β-glucopyranosyl ureas were identified 
as nanomolar inhibitors of rabbit muscle glycogen phosphorylase and might be 
applied in the therapy of type 2 diabetes mellitus.103, 104 The N-Aryl-
N’-β-glucopyranosyl ureas exhibited weaker binding to the glycogen phosphorylase 
than the acyl derivatives.103, 105 The condensation product between aldoses and urea is 
obtained from acid catalysed reactions in water or water mixtures and was first 
described for D-glucose by Schoorl et al. as early as 1900.106, 107 After minor modifications 
in the original procedure, the synthesis of glycosyl ureas was improved by Benn and 
Jones yielding 32% after 42 h with sulphuric acid as catalyst.108 The best results so far  
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were obtained by M. Sano et al. using the ion exchanger Amberlite IR-120 (H-form) to 
obtain β-D-glycosyl urea in 53% chemical yield after 4 d at 75-80 °C.100 Higher yields 
could not be achieved without significantly longer reaction times (7-14 d).99 Modern 
and more versatile methods use the reaction of glycosyl isocyanates with amines to 
prepare glycosyl ureas. These and other important synthetic approaches towards 
carbohydrate-based ureas were reviewed by Spanu et Ulgheri.109 A simple synthesis of 
α-glycosyl ureas was developed by Bianchi et al.110 
The reported methods for the preparation of β-D-glycosyl and β-D-mannosyl ureas 
suffer from moderate yields and long reaction times. An ideal method for the 
conversion of biomass into platform chemicals, however, is the use of highly 
concentrated systems featuring a high substrate concentration and high chemical 
yields. Such systems should allow efficient conversions in short reaction times.  
Here, we report the application of carbohydrate urea melts developed in our working 
group17, 18, 22, 67, 111, 112 with diverse Brønsted and Lewis acids as catalyst in aldose 
concentrations as high as 3 mol/L. Using such carbohydrate melt systems, the reaction 
times are reduced, while the yields could be significantly increased compared to the 
reported systems (up to 78%). Apart from β-D-glucosyl urea 2a, β-D-mannosyl urea 2b 
was prepared in the highest yields reported (up to 81%) so far in the literature (Scheme 
1). Glycosyl urea formation was also observed for D-galactose 6, N-acetyl-
D-glucosamin 7, L-rhamnose 8, and 2-deoxy-D-glucose 9. Moreover, we showed that 
N,N’-ethylene urea 14, N,N’-allylurea 15 and ethyl carbamate substitute in the melt at 
the C-1 position of D-glucose. 
Results and Discussion 
Formation of β–D-glucosyl urea in carbohydrate melt 
The acid catalysed condensation of D-glucose with urea in aqueous media applying 
long reaction times was described by both Benn et al.108 and Sano et al.100 The 
stereochemistry at the anomeric centre was determined based on 1H-NMR coupling 
constants of the two axial protons in C-1 and C-2 position by Helm to be the β-form.99 
Typically, the anomeric effect favours the α-configuration in sugars with 
electronegative substituents in C-1 position.113 Nitrogen has a lower electronegativity 
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compared to oxygen and halogens and thus contributes less to the anomeric 
stabilisation of glycosyl ureas. Polar solvents are known to reduce the stabilisation at 
the anomeric centre. Both effects and the steric hindrance account for the preferred 
β-glycoside configuration. 
First results for the condensation reaction were obtained using montmorillonite as 
catalyst in a D-glucose/urea/NH4Cl melt (3:7:1, wt:wt:wt). Montmorillonite, a 
phyllosilicate with Brønsted and Lewis acid character, was chosen as a catalyst because 
it is mild, non-toxic and could be recycled after the reaction since it is a heterogeneous 
catalyst. After 48 h reaction time at 80 °C, the reaction was analysed by 13C-NMR 
showing a high conversion and a high selectivity. The resonance signal for 1a at the 
anomeric centre (92.3 ppm, d6-DMSO) disappeared completely and the only carbonyl 
resonance signal detected at 158.0 ppm (d6-DMSO) indicated the selective formation of 
one isomer. The sample was analysed by mass spectrometry to confirm that urea was 
selectively mono glycosylated. The high coupling constant in the 1H-spectrum 
confirmed the β-configuration of the glycoside (Scheme 1). 
After the initial experiment, several other catalysts were tested. The product yield was 
determined by HPLC using sucrose as internal standard (Table 14). 
 
Scheme 1 Acid catalysed formation of β-form condensation products 2a and b in the melt. 
Table 14 Chemical yields for β-D-glycosyl urea 2a preparation in carbohydrate melts (2 h). 
catalyst yield [%]a 
Amberlyst 15 81 
FeCl3 27 
ZnCl2 14 
p-TsOH 37 
Montmorillonite 14 
Without catalyst 14 
aYields determined by HPLC 
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The highest yield for the glycoside 2a was 81% with Amberlyst 15 after 2 h at 80 °C 
determined by HPLC. para-toluene sulfonic acid (p-TsOH) and FeCl3 yielded 37% and 
27% of 2a, respectively. Montmorillonite and ZnCl2 displayed no catalytic reactivity. 
Additionally, the HPLC measurements showed that after 30 minutes at least 60% of 
D-glucose 1a was converted, after 2 h about 8% sugar 1a could be detected, even in the 
absence of a catalyst. The discrepancy between the low yields and the high D-glucose 
consumption is mostly due to the formation of a second product, detected as a single 
peak next to the product peak in the HPLC chromatogram. The integrals of the HPLC 
signals were compared, which is possible for the nearly quantitative ELSD detector 
due to uniform responses. After 15 minutes reaction time with Amberlyst 15, the 
amount of intermediate 3 was 10 % less than the amount of glucosyl urea 2a, whereas 
after 2 h only 7% of 3 were present. The 6-7-fold amount of the second product 
compared to glucosyl urea 2a was found without catalyst after 15 minutes and after 6 h 
still a 4-fold excess. Further LC-MS analysis proved that the unknown product exhibits 
a molecular weight of 240 g/mol which might correspond to the intermediate 3 
(Scheme 2), obtained by nucleophilic addition of urea at C-1. 
Formation of β-D-mannosyl urea in carbohydrate melt 
Based on the successful conversion of D-glucose 1a the epimer D-mannose 1b was tried 
to show the general applicability of acid catalysed condensation with urea in high 
concentration carbohydrate melts for different sugars (Scheme 1). Badawi reported an 
inefficient procedure in water with sulphuric acid as catalyst and reaction times of up 
to 7 days. 114 The yield of β-D-mannosyl urea 2b after 7 days was 12% after 
 
Scheme 2 A suggested reaction mechanism for the reaction of D-glucose 1a with urea via
intermediate 3 in a sugar-urea-salt melt under acidic conditions. 
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recrystallisation from MeOH. β-Configuration at the anomeric centre was established 
by optical rotation of the derivatives after periodate reaction, which was compared 
with the values of derivatives of β-D-glucosyl urea 2a. 
In an initial study, a melt consisting of D-mannose/urea/NH4Cl (3:7:1, wt:wt:wt) was 
stirred with Amberlyst 15 as catalyst and the purified product was analysed by NMR 
and mass spectrometry. 13C-NMR and NOE experiments confirmed the expected 
β-anomer as the reaction product and the mass spectrometric analysis indicated that 
selective mono condensation had taken place. Again, the reduced electronegativity of 
the C-1 substituent and the bulkiness of the urea moiety are the probable reasons for 
the observed stereochemistry. Quantification of the sugar ureide 2b by HPLC showed 
that optimum yields with selected catalysts were achieved after 1 h reaction time at 
80 °C.  
The best yields of condensation product 2b were obtained with FeCl3 (81%), 
Amberlyst 15 (75%), and p-TsOH (64%). Montmorillonite and ZnCl2 were also applied, 
but showed less catalytic activity and the determined yields remained below those of 
the other catalysts. In contrast to the condensation with monosaccharide 1a, only one 
product was found by HPLC. With 1 h and 2 h, respectively, for both β-D-mannosyl 2b 
and β-D-glycosyl urea 2a, the reaction times could be significantly reduced compared 
to literature.  
A fructose/urea melt was reacted under acidic conditions (Amberlyst 15) at 80 °C for 
24 h forming a mixture of condensation products which could not be separated. We 
assume that the fructose/urea condensation products are present in the furanose- and 
pyranose- as well as in the α- and β-form. 
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Reactions of further monosaccharides in the carbohydrate-urea melts 
To investigate the effects of stereochemistry on the reaction pathway and to enlarge the 
scope of application, four additional sugar/urea/NH4Cl melts (3:7:1, wt:wt:wt) were 
examined for their reaction under acidic conditions. In the depicted conformations 
(Scheme 3), D-galactose 6 has an axial OH-group in 4-position, N-acetyl-
D-glucosamine 7 is substituted with a bulky and electron-withdrawing group at 
2-position, L-rhamnose 8 shows an axial OH-group at 2-position like D-mannose, and 
in 2-deoxy-D-glucose 9, the OH-group in 2-position is replaced by a hydrogen atom 
(Scheme 3).  
After stirring the melts with the acidic Amberlyst 15 at 80 °C for 2 h, reaction control by 
13C-NMR showed that the twelve signals of the corresponding starting materials were 
reduced to six signals. As in the case of glucosyl- and mannosyl urea, the resonance 
signal for the anomeric centre had disappeared and a new carbonyl resonance was 
detected at 160 ppm (D2O). Apparently, one anomer was selectively formed, 
presumably the β-anomer. HPLC-MS measurements confirmed for all 
monosaccharides that only one product was obtained, according to the mass of the 
 
Scheme 3 Glycosyl ureas 10-13 from the acid catalysed reaction of monosaccharides 6-9 in 
melts. 
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glycosyl urea. Additionally, we observed that more than 90% of the starting material 
was converted. Neither in the samples with catalyst nor in samples without catalyst, an 
intermediate (cf. D-glucose, 3) was found. 
Reactions of D-glucose with urea derivatives under solvent-free and acidic 
conditions 
After exploring the efficient condensation of the monosaccharides 1a/b and 6-9 with 
urea, different urea derivatives and nucleophiles with similar structures to urea were 
tested as melt components to form N-glucosides (Scheme 4).  
Therefore, the lowest melting point (eutectic point) of mixtures of sugar 1a and one of 
the additive compounds 14-17 (Table 15) was determined. However, only the cyclic 
N,N’-ethylene urea 14 showed a melting point depression and a clear melt was formed. 
In all other cases, the sugar could only be suspended in an excess of the melted 
component.  
The addition of Amberlyst 15 to a 1:1 (wt:wt) mixture of cyclic N,N’-ethylene urea 14 
with D-glucose 1a followed by stirring the melt for 6 h at 75 °C afforded 27% of pure  
N-D-glucosyl-N’-ethylene urea tetraacetate 18 after acetylation and purification by 
column chromatography or recrystallisation. A corresponding mixture of the cyclic 
urea 14 with D-fructose showed the formation of the dehydratisation product HMF 
after stirring at 85 °C over night with Amberlyst 15. 
 
Scheme 4 Acid catalysed formation of condensation products 19-24 in melts. 
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Although D-glucose 1a and N-allyl urea 15 do not form a clear melt, the addition of 
Amberlyst 15 to a suspension of D-glucose/N-allyl urea (2:1, mol:mol) at 85 °C 
catalysed the condensation of the urea derivative with the C-1 position of 
compound 1a. After 2 h reaction time, sugar 1a was completely consumed and about 
50% of the unprotected product N-D-glucosyl-N’-allyl urea 19 was formed (NMR 
estimation). Due to the amphiphilic character of the molecule, only analytical amounts 
of the unprotected form could be isolated. From the large 1H-NMR coupling constant (J 
= 9.1 Hz) between the H-atom at the anomeric centre (C-1) with the H-atom on the 
adjacent carbon (C-2) in the unprotected sugar, we inferred that both H-atoms have 
axial-axial configuration, thus the β-form is favoured. HPLC measurements confirmed 
the highest yield after 2 h. Acetylation of crude 19 and purification by column 
chromatography afforded 60% of pure product 22. 
Sugar-based surfactants would be obtained by the condensation of long-chain alkyl 
ureas to saccharides. Procedures for the direct condensation of aldohexoses with such 
urea derivatives in solution are already published.115, 116 Another strategy without 
protecting groups involves the use of D-glucosylamines and alkyl isocyanates.116, 117 
Under solvent-free conditions, a number of products occurred in a suspension of 
melted N-octylurea 16 and D-glucose 1a, with varying acidic catalysts. The low 
reactivity of the long-chain alkyl ureas might be explained by the intermolecular 
Table 15 Different urea derivatives (14-17), which were reacted with D-glucose 1a; reaction 
time, temperature and yield of the product (after peracetylation). 
 
Product R3 Reaction time (h) Temperature (°C) Yield (%) 
18 
 
6 75 27 
19, 22 2 85 60 
20, 23 
 
2-24 110 - 
21, 24 
 
4 70 73 
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hydrogen bonding between alkyl ureas.118, 119 Furthermore, many products were 
generated presumably due to Maillard-like reactions or caramelisation of the sugar at 
such high reaction temperatures. 
Finally, an N-glucoside of ethyl carbamate 17 with D-glucose 1a was synthesised. 
Carbamates are structurally related to ureas, also called carbamides. They are 
established as protecting groups for amine groups and can be cleaved by various 
chemical and also enzymatic methods. Tetraacetyl-D-glucosylethylurethane was firstly 
reported by Helferich et al. and synthesised by the reaction of tetraacetyl-D-
glucosamine and ethyl chloroformate in dry pyridine.120 Another method developed by 
Sarap et al. involves the synthesis of tetra-O-acetyl-β-D-glucosyl isocyanate and its 
conversion with ethanol.121 In an initial screening of acid catalysts, FeCl3 was identified 
as the catalyst with the highest conversion. In a suspension of ethyl carbamate 17 and 
D-glucose 1a (2:1, mol:mol) with 10 mol% of the catalyst after 5 h reaction time at 70 °C, 
73% of product 24 were found after acetylation and purification. Only analytical 
amounts of the unprotected N-D-glucosyl-ethyl carbamate 21 could be isolated by our 
means. In this case, the β-anomer is the only obtained isomer again, which was 
confirmed by the large coupling constant (J= 9.3 Hz) in the 1H-NMR spectrum.  
Conclusion 
In conclusion, we have shown that carbohydrate-urea melts are suitable reaction media 
to synthesise N-glycosides efficiently in high yields (up to 81%) under mild reaction 
conditions and high concentrations. The readily available starting materials consist 
mainly of renewables and cheap bulk chemicals. In a one-step reaction and without the 
need of protecting groups, the β-anomer was formed selectively. Our data imply that 
the reaction of D-glucose may proceed via an intermediate O,N-hemiacetal formed by 
the addition of the nucleophile to C-1. D-Glucose, D-mannose, D-galactose, N-acetyl-
D-glucosamin, L-rhamnose, and 2-deoxy-D-glucose were converted likewise and the 
scope of the melt condensation reaction includes N-substituted ureas and carbamates. 
The here reported glycosyl urea synthesis is superior to previously reported pro-
cedures as it is very simple and efficient. 
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Experimental 
General. All chemicals were used for syntheses as received without further 
purification. N-octylurea 16 was prepared according to Kehm.122 IR spectra were 
recorded with a Bio-Rad FT-IR-FTS 155 spectrometer. Melting points were determined 
by an Optimelt MPA 100 apparatus from Stanford Research Systems. 
NMR Spectra were recorded on a Bruker Avance 600 (T= 300 K). The spectra are 
referenced against the internal NMR-solvent standard and chemical shifts are reported 
in ppm. 
HPLC measurements 
Glucosyl urea 2a: The HPLC measurements were conducted with a Phenomenex Luna 
3u HILIC 200 Å, 150 x 2.00 mm column, LC system Agilent 1100, Varian PL-ELS 2100 
Ice (30 °C) as detector, and run with MeCN/H2O/100 mM NaOAc 90:5:5 as eluent. The 
column temperature was 40 °C, the injection volume 0.1 μL, while a flow rate of 
0.3 mL/min and sucrose as internal standard was used. The system was run with 
ChemStation for LC 3D Systems Rev. B.03.02 as software. 
Mannosyl urea 2b: The HPLC measurements were conducted with a Phenomenex 
Luna 3u HILIC 200 Å, 150 x 2.00 mm column, LC system Agilent 1100, Varian PL-ELS 
2100 Ice (30 °C) as detector, and run with MeCN/H2O/100 mM NaOAc 90:5:5 as eluent. 
The column temperature was 25 °C, the injection volume 0.5 μL, while a flow rate of 
0.3 mL/min and sucrose as internal standard was used. The system was run with 
ChemStation for LC 3D Systems Rev. B.03.02 as software. 
Typical procedure for the preparation of β-D-glucosyl urea (2a) 
D-Glucose (0.6 g, 3.3 mmol), urea (1.4 g, 26.7 mmol) and NH4Cl (0.2 g, 3.7 mmol) were 
molten in a 25 mL reaction flask at 80 °C until a clear melt was formed. Amberlyst 
(0.2 g) was added and the reaction was stirred for 2 h at that temperature. After the 
reaction was finished, water was added to the still warm melt and the catalyst was 
filtered off. After the removal of the water, the brownish solid was twice recrystallised 
from MeOH to give pure β-D-glucosyl urea as white crystals (0.47 g, 64%). (For 
characterisation data see lit. 99). 
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β-D-Mannosyl urea (2b) 
D-Mannose (0.6 g, 3.3 mmol), urea (1.4 g, 26.7 mmol) and NH4Cl (0.2 g, 3.7 mmol) were 
molten in a 25 mL reaction flask at 80 °C until a clear melt was formed. Amberlyst 15 
(0.2 g) was added and the reaction was stirred for 1 h at that temperature. After the 
reaction was finished, water was added to the still warm melt and the catalyst was 
filtered off. After the removal of the water, the brownish solid was twice recrystallised 
from MeOH to give a mixture of β-D-mannosyl urea and urea. Urea was degraded by 
urease in an aqueous solution, the urease was filtered off and after freeze-drying, pure 
β-D-mannosyl urea was obtained as a white powder (0.53 g, 72%). 
1H-NMR (600 MHz, DMSO-d6): δ [ppm] = 2.97-3.03 (m, 1 H), 3.24-3.34 (m, 2 H), 3.36-
3.43 (m, 1 H), 3.50-3.52 (m, 1 H), 3.59-3.65 (m, 1 H), 4.41 (t, J = 6,0 Hz, 1 OH), 4.67 d (d, 
J = 5,0 Hz, 1 OH), 4.76 (d, J = 5,4 Hz, 1 OH), 4.80 (m, 1 H), 4.83 (d, J = 5,4 Hz, 1 OH), 5.84 
(s, NH2), 6.47 (s, NH); 13C-NMR (150 MHz, DMSO-d6): δ [ppm] = 61.41, 66.88, 71.22, 
74.39, 78.30, 78.46, 157.53; FT-IR (ATR): v [cm-1] = 3334, 3244, 2942, 2358, 1663, 1614, 
1528, 1446, 1411, 1377, 1200, 1140, 1076, 1047, 1024, 958, 863, 801,614, 539: MP: 178 °C; 
LSI-MS (glycerol): m/z (%) = 223.1 (100) [MH+], 315.3 (43) [MH+ + glycerol]; LSI-MS: 
calcd.: 223.0930, found: 223.0933. 
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NOE spectrum for β-D-mannosyl urea (2b) 
Typical procedure for the preparation of β-D-glycosyl ureas (10-14) 
Monosaccharide 7-10 (0.6 g, 3.3 mmol), urea (1.4 g, 26.7 mmol) and NH4Cl (0.2 g, 
3.7 mmol) were molten in a 25 mL reaction flask at 80 °C until a clear melt was formed. 
Amberlyst (0.2 g) was added and the reaction was stirred for 2 h at that temperature. 
After the reaction was finished, D2O/H2O was added to the still warm melt and 
reaction mixtures were directly used for further measurements.  
D-Galactosyl urea (10) 
13C-NMR (75 MHz, D2O): δ [ppm] = 61.1, 68.8, 69.6, 73.5, 76.3, 81.4, 160.7.  
ESI-MS: m/z (%) = 445.1 [2 MH+] (100), 223.1 [MH+] (46). 
N-Acetyl-D-glucosaminyl urea (11) 
13C-NMR (75 MHz, D2O): δ [ppm] = 22.1, 54.3, 60.71, 69.7, 74.3, 77.2, 80.2, 160.4, 174.9. 
ESI-MS: m/z (%) = 264.1 [MH+] (100), 527.2 [2 MH+] (53). 
The H-1/H-5 and H-1/H-3 NOE contacts in the β-conformation are clearly observed. 
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L-Rhamnosyl urea (12) 
13C-NMR (75 MHz, D2O): δ [ppm] = 16.8, 70.6, 71.8, 73.2, 73.3, 78.7, 160.0.  
ESI-MS: m/z (%) = 413.1 [2 MH+] (100), 207.1 [MH+] (35). 
2-Deoxy- D-glucosyl urea (13) 
13C-NMR (75 MHz, D2O): δ [ppm] =37.4, 61.0, 70.8, 71.1, 77.2, 77.6, 160.2.  
ESI-MS: m/z (%) = 207.1 [MH+] (100), 413.1 [2 MH+] (66). 
Preparation of N-D-Glucosyl-N’-ethylene urea-tetraacetate (18) 
A melt of D-glucose (0.5 g, 2.8 mmol) and N,N’-ethylene urea (0.5 g, 5.8 mmol) was 
stirred with 50 mg of Amberlyst 15 for 6 h at 75 °C. After addition of water, filtering off 
the catalyst and freeze-drying, the white solid was heated to 90 °C in a mixture of Ac2O 
(2.2 mL, 23.3 mmol) and NaOAc (0.4 g, 4.9 mmol) for 1.5 h. Then, the solution was 
poured into saturated NaHCO3 solution and the aqueous phase was extracted three 
times with CH2Cl2. The combined organic layers were washed twice with water. 
A colourless solid was obtained after recrystallisation from EtOAc/PE (4:1) (0.3 g, 27%). 
1H-NMR (300 MHz, D2O): δ [ppm] = 2.00, 2.02, 2.03, 2.06 (4x s, 12 H), 3.33-3.47 (m, 2 H), 
3.56-3.61 (m, 2 H), 3.77-3.83 (m, 1 H), 4.04-4.10 (m, 1 H), 4.21-4.26 (m, 1 H), 5.01-5.17 (m, 
4 H), 5.26-5.32 (m, 1 H). 13C-NMR (75 MHz, D2O): δ [ppm] = 20.7, 20.7, 20.8, 20.9, 38.2, 
39.7, 60.0, 68.3, 68.3, 73.5, 73.6, 80.6, 161.7, 169.7, 170.0, 170.8. FT-IR (ATR): v [cm-1] = 
2896, 1738, 1673, 1486, 1434, 1369, 1214, 1127, 1034, 900, 842, 765, 697, 599, 495, 461, 436. 
MP: 154 °C, ESI-MS: m/z (%) = 434.0 [MNH4+] (100), 417.0 [MH+] (76). 
Preparation of N-D-glycosyl-N’-allyl urea (19) 
A slurry of D-glucose (5.0 g, 0.03 mol) and N,N’-allyl urea (5.5 g, 0.05 mol) was stirred 
with 2 g of Amberlyst 15 for 6 h at 85 °C. After addition of water, the solid catalyst was 
filtered off and the aqueous solution decolourised with charcoal and freeze-dried. The 
sample was subsequently subjected to Soxhlet extraction with EtOAc over three days, 
in which the solvent was exchanged after 24 h. Finally, a colourless powder 
precipitated from the EtOAc layer which was the product (54 mg, 0.7%). 
1H-NMR (300 MHz, D2O): δ [ppm] = 3.32-3.91 (m, 8 H), 4.83 (d, J=9.06 Hz, 1 H), 5.11-
5.22 (m, 2 H), 5.94 (m, 1 H); 13C-NMR (75 MHz, D2O): δ [ppm] = 41.93, 60.74, 69.48, 
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72.01, 73.20, 76.62, 77.11, 81.15, 114.88, 135.00, 159.58; FT-IR (ATR): v [cm-1] = 3300, 
2920, 1639, 1557, 1420, 1363, 1272, 1073, 1012, 921, 559; MP: 136 °C (decomp.); ESI-MS: 
m/z (%) = 525.2 [2 MH+] (100) 263.1 [MH+] (32), GC-MS (SiMe3): m/z (%) = 479.0 [MH+-
SiMe3] (100), 496.1 [MNH4+] (64). 
Preparation of N-D-glycosyl-N’-allyl urea-tetraacetate (22) 
A slurry of D-glucose (1.0 g, 5.5 mmol) and N,N’-allyl urea (1.1 g, 11.1 mmol) was 
stirred with 0.4 g Amberlyst 15 for 2 h at 85 °C. After addition of 6 mL Ac2O (63 mmol) 
and 0.9 g sodium acetate (11 mmol), the mixture was heated to 90 °C for 2 h. The 
reaction was stopped by pouring the cool solution into saturated NaHCO3 solution. 
Then, the aqueous phase was extracted three times with EtOAc, the combined organic 
layers were washed with water, dried over MgSO4 and evaporated. The crude product 
was purified by flash chromatography (EtOAc:PE = 2:1) affording a colourless solid 
(1.4 g, 60%). 
1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.99, 2.00, 2.03, 2.05 (s, 12 H), 3.84 (m, 2 H), 4.06 
(dd, J1=1.92 Hz, J2=12.35 Hz, 1H), 4.30 (dd, J1=4.39 Hz, J2=12.35 Hz, 1H), 4.86-5.31 (m, 
6H), 5.70 (d, J=9.39 Hz), 5.75-5.90 (m, 1H); 13C-NMR (75 Hz, CDCl3): δ [ppm] = 20.69, 
20.85, 42.86, 68.46, 70.66, 73.08, 73.24, 80.24, 116.10, 134.87, 156.58, 169.79, 170.03, 170.81, 
171.08; FT-IR: v [cm-1] = 3319, 2948, 1739, 1637, 1580, 1434, 1373, 1210, 1096, 1030, 907, 
674, 599, 490, 464; MP: 131 °C ESI-MS: m/z (%) = 448 [MNH4+] (100), 431 [MH+] (78). 
Preparation of N-D-glycosyl-O-ethyl carbamate (21) 
A slurry of D-glucose (0.4 g, 2.2 mmol) and N-ethyl carbamate (0.4 g, 4.5 mmol) was 
stirred with 20 mol% FeCl3*6H2O for 2.5 h at 80 °C and the excess of carbamate was 
removed by ultrasonic extraction with EtOAc (3×10 mL) and an extraction time of one 
hour. The residual solid was solved in a small amount of MeOH and dropped into ice-
cooled Et2O. Finally, the Et2O phase was evaporated and a colourless solid was 
obtained (18 mg, 3 %). 
1H-NMR (300 MHz, DMSO-d6): δ [ppm] = 1.16 (t, J=7.14 Hz, 3 H), 9.97-3.63 (m, 8 H), 
3.99 (q, J=7.04 Hz, 2 H), 4.43-5.18 (m, 3 H), 7.73 (d, J=9.33 Hz, 1 H); 13C-NMR (75 MHz, 
DMSO-d6): δ [ppm] = 14.53, 59.68, 60.80, 69.77, 71.83, 77.39, 78.18, 82.22, 155.94; 
1H-NMR (300 MHz, D2O): δ [ppm] = 1.14 (t, J=7.14 Hz, 3 H), 3.22-3.79 (m, 6 H),  
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4.05 (q, J=6.95 Hz, 2 H), 5.32 (d, J=5.49 Hz, 1 H); 13C-NMR (75 MHz, D2O): δ [ppm] = 
13.73, 60.58, 62.41, 69.26, 71.76, 76.48, 77.27, 81.75, 158.48; FT-IR: v [cm-1] = 3122, 3037, 
2817, 2674, 2361, 2323, 1607, 1558, 1402, 1253, 1180, 1120, 421; MP: 182 °C (decomp.); 
ESI-MS: m/z (%) = 269.1 [MNH4+] (100), 252.1 [MH+]. 
Preparation of N-D-glycosyl-O-ethyl carbamate-tetraacetate (24) 
A slurry of D-glucose (0.4 g, 2.2 mmol) and N-ethyl carbamate (0.4 g, 4.5 mmol) was 
stirred with 10 mol% FeCl3*6H2O for 4.5 h at 70 °C in a 10 mL reaction tube. After 
addition of water, FeCl3 was precipitated with aqueous NH3, filtered off and the 
remaining was solution freeze-dried. Then, NaOAc (0.5 g 2.2 mmol) and 3 mL Ac2O 
were added and the mixture was stirred at 90°C for 1.5 h in a round bottom flask. The 
content of the flask was poured into 20 mL of ice water which was extracted three 
times with CH2Cl2.The combined organic phases were washed with saturated NaHCO3 
solution and water, dried over MgSO4 and the solvent was evaporated. After 
recrystallisation from Et2O/PE, a colourless solid was obtained (yield: 73%). 
1H-NMR (300 MHz, DMSO-d6): δ [ppm] = 1.18-1.26 (m, 3 H), 1.97, 1.99, 2.02, 2.04 (4x s, 
12 H), 3.77 (m, 1 H), 4.03-4.15 (m, 3 H), 4.25-4.29 (m, 1 H), 4.85-5.28 (m, 3 H), 6.02 (d, 
J=9.62 Hz, 1 H); 13C-NMR (75 MHz, DMSO-d6): δ [ppm] = 14.4, 20.6, 20.7, 20.8, 22.1, 
61.8, 68.2, 70.3, 72.9, 73.3, 80.8, 155.7, 169.6, 170.0, 170.7; FT-IR: v [cm-1] =2961, 1736, 
1531, 1434, 1367, 1211, 1094, 1029, 908, 782, 599, 554, 484; MP: 105 °C (lit.: 104 °C)120 ESI-
MS: m/z (%) = 437.0 [MNH4+] (100), 420.0 [MH+] (70). 
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5-(α-D-Glucosyloxymethyl)furfural 2, a versatile building block from renewable 
resources, was prepared from isomaltulose 1-choline chloride melts by acid catalysis. 
In this solvent-free process, moderate yields were achieved under mild reaction 
conditions. 
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Introduction 
Building blocks from renewable resources will gain importance due to the limited 
natural resources of fossil starting materials for organic synthesis. As carbohydrates 
amount to 75% of the annually renewable biomass,123 they could provide organic 
carbon for a variety of intermediate chemicals.124  
5-Hydroxymethylfurfural (HMF) is one of the top value added chemicals from 
biomass.125 Hexoses, for example, are converted to HMF upon acid catalysed 
dehydration. In comparison between different monosaccharides, D-fructose provides 
the highest yields.126 5-(α-D-Glucosyloxymethyl)furfural (GMF) 2 is formed by thermal 
decomposition of isomaltulose (= palatinose) 1127 and was also isolated from steamed 
Radix Rehmanniae and from Amelanchier fruits. 128, 129 It is also generated when 
heating HMF with glucose in 1,4-dioxane.130 Originally, it was synthesised in the group 
of Lichtenthaler in high yields starting from isomaltulose 1 using DMSO as solvent.131, 
132 The mixture was heated to 120 °C for 4 h with a strongly acidic, sulfonic acid type 
ion exchange resin. Resulting mixtures consisted of GMF 2 (65-70%), isomaltulose 
dimers (10%), HMF, glucose (5-10%), and starting material (10%) determined by HPLC. 
The starting material isomaltulose 1 is commercially produced from sucrose in an 
enzymatically catalysed 1,6-glycosyl shift.133 The fructosyl moiety of isomaltulose 1 was 
dehydrated to a furfural derivative, while the glucosyl residue was stable.  
GMF 2 was used as building block for a variety of derivatisation reactions to obtain the 
furancarboxylic acid, GMF-nitrile, the GMF-amine via reductive amination, or aldol-
type reaction products.131  
Ionic liquids or deep eutectic solvents are considered as alternatives to hazardous 
solvents.134 In our working group, sugar-urea-salt mixtures were developed as 
alternative solvents for organic reactions.17-19 Furthermore, glycosyl ureas could be 
synthesised in high yields in these melts.135 Ilgen et al. used carbohydrate–choline 
chloride melts to produce HMF from the carbohydrate content.67 Likewise, Han et al. 
converted inulin to HMF in choline chloride/citric acid or choline chloride/oxalic acid 
melts.136  
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Adopting the concept of dehydration of hexoses in choline chloride melts, we now 
report the preparation of GMF 2 in an isomaltulose 1–choline chloride melt by different 
acidic catalysts under mild reaction conditions in good yields (Scheme 5). 
Advantages of such sugar melts are the omission of solvents like DMSO, the low 
vapour pressure of the liquid, and the exclusive use of non-toxic, renewable 
compounds.  
Results and Discussion 
The sugar–choline chloride mixture with the lowest melting point contained both 
compounds in a 1:1 ratio (wt/wt) which corresponds to a carbohydrate concentration of 
1.7 mol/L in the melt. Though the water content of the melts is low (approx. 2%), a pre-
drying at 90 °C and 10 mbar vacuum was necessary to remove most of the water. 
Water causes the hydrolysis of GMF 2 to D-glucose and HMF. Furthermore, the 
reaction was performed under vacuum to remove water which is generated during the 
dehydration reaction to suppress the decomposition. 
The catalytic activity was evaluated for different acids at three different temperatures 
(90 °C, 100 °C, 110 °C) and at regular time intervals (15, 30, 60, 90 min). Amberlyst 15 is 
an inexpensive and strongly acidic ion exchange resin. It can easily be handled and 
removed by simple filtration. Montmorillonite is also a non-toxic, non-corroding solid 
ion exchanger. para-toluenesulfonic acid (p-TsOH) is a water-soluble, strong organic 
acid. FeCl3 is a hygroscopic and strong Lewis acid. ZnCl2 is also hygroscopic with a 
moderate Lewis acidity.  
 
 
 
Scheme 5 Dehydration of isomaltulose 1 to α-GMF 2 under acidic conditions. 
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The content of isomaltulose 1, GMF 2, D-glucose, and HMF in the samples was 
quantified by HPLC. Optimum GMF yields were obtained after 15 min at 100 °C, 
similar to those at 90 °C (with a difference of at most 3%, Table 16). At 110 °C, less 
GMF 2 was found; simultaneously the HMF content increased. Generally, more HMF  
was formed, when the temperature was raised. The HMF yields were between 6% with 
Montmorillonite and 60% with FeCl3 as catalyst at 100 °C. However, with longer 
reaction times, the yields dropped due to the formation of HMF polymers and humins, 
which is known to occur in concentrated solutions.137 
D-Glucose was mainly found in the samples which were not pre-dried before addition 
of the catalyst, however only in amounts between 12 and 14%. Additionally, it was 
found in all the samples with Amberlyst 15 (3-6%) and FeCl3 (2-3%). The starting 
material palatinose was only detected in the samples with Montmorillonite and ZnCl2 
when no pre-drying was applied (7 and 84%, respectively).  
Reaction of isomaltulose with urea  
Isomaltulose 1, or 6-O-α-D-glucopyranosyl-D-fructose, formed also a low melting 
mixture with urea and the same reaction conditions as for the aldoses, like glucose and 
mannose (chapter 2), were applied. The most electrophilic carbon atom is that at the 
anomeric carbon atom of the fructosyl moiety. As the 6-OH group is locked at the 
D-glucose part, only two furanoid forms are predominant in solution: β-f-form : 
α-f-form : acyclic form = approx. 25% : 72% : 3%.138  
Table 16 GMF 2 yields for different catalysts under optimised conditions (temperature and 
time). 
Entry Catalyst T (°C) t (min) Yield (%) 
1 ZnCl2 100 60 52 
2 Montmorillonite 100 15 46 
3 Amberlyst 100 15 34 
4 p-TsOH 100 15 35 
5 FeCl3 100 15 27 
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An isomaltulose 1-urea melt (3:7:1 wt/wt) was allowed to react with Amberlyst for 2 h 
at 80 °C (Scheme 6). First analysis of the crude reaction mixture by 13C-NMR showed 
the presence of isomaltulose and the typical peak at about 160 ppm next to the urea 
peak, indicating the formation of a glycosyl urea. After acetylation and column 
chromatography, pure isomaltulosylurea heptaacetate (α-anomer) was isolated in 11% 
yield and fully characterised. The correct assignment of the signals of the 
(2R)-configured furanosid was only possible by two-dimensional NMR spectra. 
Furthermore, we inferred from TLC, LC-MS and NMR that the β-anomer was formed 
in 15% yield.  
Conclusion 
In summary, we have converted isomaltulose to GMF 2 in the presence of catalysts 
without any solvent, but in highly concentrated (50 wt% of sugar), environmentally 
benign sugar – choline chloride melts. Highest yields were obtained for ZnCl2 as 
catalyst. However, in view of the shorter reaction times required, the handiness, and 
the recyclability, the use Montmorillonite would be preferable. The isolated GMF 2 
yields are currently still lower than in the comparable DMSO solution process. 
However, the reported direct conversion in neat melt without added organic solvents 
may be of interest as an alternative very simple and non-toxic process for GMF 
synthesis. 
In addition, we reported for the first time that acidic conditions catalyse the addition of 
urea to the C-2 atom of the fructosyl moiety of isomaltulose in low melting sugar-urea 
mixtures. 
 
 
Scheme 6 Reaction of isomaltulose 1 with urea to N-(2,3,4,6,1',3',4'-hepta-O-acetyl-L-
isomaltulosyl) urea 3 under acidic conditions. 
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Experimental 
General. Commercial reagents and starting materials were purchased from Aldrich, 
Fluka or Acros and used without further purification. Isomaltulose and pure GMF as 
reference were kind gifts of the Suedzucker AG. Flash chromatography was performed 
on silica gel (Merck silica gel Si 60 40-63 μm); products were detected by TLC on 
aluminium plates coated with silica gel (Merck silica gel 60 F254, thickness 0.2 mm) and 
visualised with 10% H2SO4 or KMnO4 staining solution. Melting points were 
determined with Optimelt MPA 100 and are uncorrected. NMR spectra were recorded 
with Bruker Avance 300 (1H: 300.1 MHz; 13C: 75.5 MHz; T = 300 K), Bruker Avance 400 
(1H: 400.1 MHz; 13C: 100.6 MHz; T = 300 K) and Bruker Avance 600 Kryo 
(1H: 600.2 MHz; 13C: 150.9 MHz; T=298 K) instruments. Chemical shifts are reported in 
δ/ppm relative to the external standards and coupling constants J are given in Hz. 
Abbreviations for the characterisation of the signals: s = singlet, d = doublet, t = triplet, m = 
multiplet, bs = broad signal, dd = double doublet. The relative number of protons is 
determined by integration. Error of reported values: chemical shift: 0.01 ppm (1H NMR), 
0.1 ppm (13C NMR), coupling constant: 0.1 Hz. The used solvent for each spectrum is 
reported.  
Mass spectra were recorded on a ThermoQuest Finnigan TSQ 7000 LC/MS 
spectrometer (low resolution), high resolution spectra (HRMS) on an Agilent Tech 6540 
UHD Accurate Mass Q-TOF LC/MS and with Finnigan MAT TSQ 7000 (ESI) 
spectromter, IR spectra with a Bio-Rad FT-IR-FTS 155 spectrometer and UV/VIS spectra 
with a Cary BIO 50 UV/VIS/NIR spectrometer (Varian). Optical rotation was 
determined with Krüss optronic P8000T. 
General procedure for the preparation of GMF 2 
In a 10 mL Schlenk tube, a pestled mixture of isomaltulose (0.5 g, 1.5 mmol) and 
choline chloride (0.5 g, 3.6 mmol) were melted and dried at 90 °C under reduced 
pressure (10 mbar) for 2 h. Then, 10 mol% of catalyst (ZnCl2, p-TsOH or FeCl3) or 
250 mg of heterogeneous catalyst (Montmorillonite or Amberlyst 15) were added. All 
analytical data were in accordance with those in the literature.131 
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Preparation of the HPLC samples 
The complete reaction batch was dissolved in 30 mL of millipore water. The HPLC 
measurements were conducted with a Phenomenex Luna 3u HILIC 200 Å, 150 x 2.00 
mm column, LC system Agilent 1100, Varian PL-ELS 2100 Ice (30 °C) as detector, and 
run with MeCN/H2O/100 mM NaOAc 90:5:5 as eluent. The column temperature was 
40 °C, the injection volume 0.1 μL, while a flow rate of 0.3 mL/min and sucrose as 
internal standard was used. The system was run with ChemStation for LC 3D Systems 
Rev. B.03.02 as software. 
Retention times in analytical HPLC: 
Rt (HMF, DAD) = 1.55 min, Rt (GMF, DAD) = 2.19 min, Rt (Glucose, ELSD) = 3.82 min, 
Rt (Isomaltulose, ELSD) = 6.51 min. 
N-(2,3,4,6,1',3',4'-Hepta-O-acetyl-L-isomaltulosyl) urea 3 
Isomaltulose (1.2 g, 3.5 mmol), urea (1.4 g, 26.7 mmol), and NH4Cl (0.2 g, 3.7 mmol) 
were heated in a 10 mL reaction flask at 80 °C until a clear melt was formed. 
Amberlyst 15 (200 mg) was added and the reaction mixture was stirred for 2 h at that 
temperature. Methanol was added, solids filtered off, and the solvent evaporated. 
Then, 6 mL (5.8 g, 74.3 mmol) of pyridine and 6 mL of Ac2O (6 mL, 6.5 g, 63.5 mmol) 
were added to the mixture and the mixture was first stirred for 1 h in an ultra-sound 
bath, then over night at room temperature without sonication. The reaction was 
stopped by pouring the solution into saturated NaHCO3 solution. The aqueous phase 
was extracted three times with CH2Cl2. The combined organic layers were washed 
twice with 2N HCl, twice with water, and were finally dried over MgSO4 and 
evaporated. The crude product was purified by column chromatography (SiO2, 
CH2Cl2/MeOH 95:5), Rf =0.11 (α-anomer) (0.36 mg, 15%), Rf =0.03 (β-anomer) (0.23 mg, 
10%). 
3. Solvent-free preparation of 5-(α-D-glucosyloxymethyl) furfural from isomaltulose- choline 
chloride melts and Synthesis of N-(2,3,4,6,1',3',4'-hepta-O-acetyl-L-isomaltulosyl)urea 
 48
β -Anomer 
1H-NMR (600 MHz, CDCl3): δ [ppm] = 2.02-2.13 (7×s, 7×3H, OAc), 3.63 ((pseudo-dd, 
2J(H-6’a, H-6’b) = 9.45 Hz, 3J(H-6’a, H-5) = 1.29 Hz, 1H, H-6'a), 3.97 (dd, 3J(H-5, H-6’b) = 
1.28 Hz, 2J(H-6’a, H-6’b) = 10.80 Hz, 1H, H-6’b), 3.99-4.02 (m, 1H, H-5’), 4.13 (dd, 3J(H-6a, 
H-5) = 1.88 Hz, 2J(H-6’a, H-6’b) = 12.27 Hz, 1H, H-6a), 4.26-4.30 (m, 2H, H-6b, H-4), 4.48 
(bs, 2H, H-1’), 4.91 (dd, 2J(H-2, H-1) = 3.90 Hz, 2J(H-2, H-3) = 10.32 Hz, 1H, H-2), 5.10 (d, 
2J(H-1, H-2) = 3.90 Hz, 1H, H-1), 5.15-5.18 (m, 2H, H-5, NH), 5.38-5.43 (m, 3H, H3, H3’, 
NH), 5.57 (dd, 2J(H-4, H-3) = 7.35 Hz, 2J(H-4, H-5) = 7.24 Hz, 1H, H-4); 13C-NMR (75 Hz, 
CDCl3): δ [ppm] = 20.5, 20.6, 20.6, 20.6, 20.7, 20.7, 20.8 (CH3-Ac), 61.4 (C-6), 64.6 (C-1’), 
66.6 (C-6’), 67.4 (C-5), 67.8 (C-4), 70.1 (C-3), 71.0 (C-2), 73.4 (C-4’), 77.1 (C-3’), 77.5 (C-5’), 
90.3 (C-2’), 96.1 (C-1), 157.5 (C=O, urea), 169.3, 169.8, 170.1, 170.2, 170.3, 170.6, 170.6 
(C=O, OAc); FT-IR (ATR): v [cm-1] = 1739, 1690, 1590, 1524, 1436, 1367, 1211, 1031, 958, 
897, 775, 635, 598; MP: 84-86 °C; ESI-MS: m/z (%) = 696.3 (MNH4+, 100), 679.2 (MH+, 
78); [ ]20Dα = +82.397 (c 1.011, chloroform). 
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NOE spectrum for β- N-(2,3,4,6,1',3',4'-Hepta-O-acetyl-L-isomaltulosyl) urea 3 
The H-1'/H-3' NOE contacts in the β -conformation are observed. 
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α-Anomer 
1H-NMR (400 MHz, CDCl3): δ [ppm] = 2.00-2.10 (7×s, 7×3H, OAc), 3.64-3.67 (m, 1H, 
H-6’a), 3.85-3.89 (m, 1H, H-6’b), 4.06-4.13 (m, 2H, H-5, H6a), 4.24-4.27 (m, 2H, H-1’,H-6b), 
4.35-4.41 (m, 2H, H-1’, H-5’), 4.86 (dd, 1H, H-2), 5.04-5.13 (m, 4H, H-1, H-3’, H-4’, NH), 
5.34-5.43 (m, 1H, H-3), 5.72 (bs, 1H, H-4); 13C-NMR (75 Hz, CDCl3): δ [ppm] = 20.7-20.8 
(CH3-Ac), 61.7 (C-6), 62.7 (C-1’), 67.5 (C-5), 67.6 (C-6’), 68.4 (C-4’), 70.1 (C-3), 70.8 (C-2), 
77.0 (C-3’), 79.8 (C-5’), 79.8 (C-4), 91.7 (C-2’), 95.9 (C-1), 157.8 (C=O, urea), 169.6-, 170.8 
(C=O, OAc); FT-IR (ATR): v [cm-1] = 1740, 1695, 1546, 1435, 1367, 1216, 1031, 898, 770, 
600; MP: 84-86 °C; ESI-MS: m/z (%) = 696.3 (MNH4+, 100), 679.3 (MH+, 20). 
[ ]20Dα = 98.523 (c 1.013, chloroform). 
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4. Condensation and dehydration reactions of L-sorbose in 
eco-friendly melt systems 
 
 
L-Sorbose 1 was converted to 5-hydroxymethylfurfural 8 in choline chloride melts in 
moderate yields. A simplified synthesis of sorbosylurea tetraacetate 4 in two steps 
using urea melts was performed achieving average yields.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C. Ruß, A. Haji Begli, B. König  
“Condensation and dehydration reactions of L-sorbose in eco-friendly melt systems” 
Synth. Commun., 2012, accepted. 
 
Synthesis and characterisation were performed by C. Ruß 
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Introduction 
In 2011, a review by Zebiri et al. criticises the fact that the use of L-sorbose in organic 
chemistry is exceedingly poor and they encourage the development of new synthetic 
methods.139 For this reason, reactions of L-sorbose in the unconventional carbohydrate 
melts developed in our working group were examined.17-19 Low melting mixtures allow 
the conversion of biomass at high concentration into valuable intermediates. 
L-Sorbose is one of the rare natural L-sugars and is mainly used as starting material in 
the synthesis of vitamin C. Therefore, it is the most readily available L-sugar on large 
scale.139, 140 As 5-epimer of D-fructose, its structural similarity would suggest a 
comparable reactivity. Both, fructose and sorbose form a mixture of two pyranoid 1 
and two furanoid stereoisomers 3 (plus negligible amounts of acyclic form 2) (Scheme 
7). The composition is not only strongly dependent on the solvent employed, but also 
on the temperature.141, 142 Simple derivatisation reactions with fructose often yield 
product mixtures.140 In contrast to fructose, sorbose highly favours the α-pyranoid 
form in solution: in water, the α-pyranoid form amounts to 87-98 % in a temperature 
range of 25-85 °C.141 The benefit of sorbose is that reactions to pyranosid derivatives are 
proceeding in a more uniform manner and allow better yields than in the case of 
fructose.  
We therefore investigated the reaction behaviour of L-sorbose in four carbohydrate 
melts: urea, dimethylurea, ethylene urea and choline chloride melts. Significant 
conversions were only observed in urea and choline chloride melts. 
Results and Discussion 
From our former investigations we know that glycosyl ureas are formed in 
carbohydrate-urea melts.135 L-sorbose also forms stable melts with urea giving a 
melting point of 79-80 °C. Under acidic conditions, approx. 30% of the L-sorbose were 
mainly converted to sorbosyl urea 4 after 1.5 h reaction time at 80 °C (estimated by 
 
Scheme 7 Pyranose 1 and furanose 3 form and acyclic form of L-sorbose 2. 
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13C-NMR) (Scheme 8). Most of the starting material was recovered, but degradation to 
5-hydroxymethyl furfural (5-HMF) and to brown humins was also observed, especially 
for longer reaction times and at higher temperatures. The isolated peracetylated 
sorbosyl urea 4 has (2R)-configuration (α-anomer) which was ascertained by NOESY 
experiments. A second fraction was an inseparable mixture presumably composed of 
sorbosyl acetate, the β-anomer sorbosyl urea 4, and the sorbosylbiuret, inferred from 
13C-NMR spectra and ESI-MS measurements. 
The synthesis of the peracetylated derivative 4 was reported by Tokuyama and 
Katsuhara in 1966 (Scheme 9).143 They obtained the sorbopyranosyl urea 4 (both, 
α-anomer and β-anomer in 15% yield) by ammonolysis of the isocyanate 6 starting 
from 1,3,4,5-tetra-O-acetyl-L-sorbopyranosyl chloride 5. 
Our previous investigations showed that choline chloride melts promote the 
production of 5-hydroxymethylfurfural 8 (5-HMF) from carbohydrates.67 The 
production of 5-HMF from L-sorbose has already been patented in 1948 by Haworth 
(yield: 23%)144 and was later investigated in organic solvents catalysed by 
lanthanide(III)ions (61.4%)145, and subcritical water by Asghari et al. (50%).146 Other 
reaction conditions to make 5-HMF from different sugars were recently reviewed.147, 148  
As expected, the only product from a choline chloride-sorbose melts was 5-HMF 8 
(Scheme 10). After 1.5 h at 80 °C under acidic conditions using Amberlyst 15 as 
catalyst, the starting material was completely consumed and 24% of 5-HMF were 
obtained.  
 
Scheme 8 Synthesis N-(1,3,4,5-tetra-O-acetyl-L-sorbopyranosyl)urea 4 in sorbose-urea melts 
under acidic conditions.  
Scheme 9 Synthesis of N-(1,3,4,5-tetra-O-acetyl-L-sorbopyranosyl)urea 4 according to 
Tokuyama.143 
 
4. Condensation and dehydration reactions of L-sorbose in eco-friendly melt systems 
 54
Under the same reaction conditions used by Ilgen et al. (100 °C, 0.5 h, 10% p-TsOH),67 
L-sorbose yielded only 11% of HMF while 67% were received starting from D-fructose. 
The lower 5-HMF yields starting from L-sorbose were previously observed by Seri et 
al.145 and by Asghari et al.146 They suggested that the different configurations of the 
hydroxyl groups at the C-3 and the C-4 atom in L-sorbose impair the dehydration 
reaction leading to lower yields.  
Conclusion 
In summary, new reactions of L-sorbose were investigated using low melting 
carbohydrate mixtures as eco-friendly reaction medium. We showed that the 
important intermediate 5-HMF can be produced from L-sorbose in choline chloride 
melts under acidic conditions.  
Furthermore, a new, time-saving synthesis of sorbosylurea tetraacetate 4 is reported 
here. Using urea melts, we successfully simplified the literature known four step 
synthetic route to a two step procedure starting from unprotected L-sorbose, without 
the need of expensive reagents and inconvenient reaction conditions. For the first time, 
the structure of the selectively formed α-pyranose form was proven by two-
dimensional NMR techniques. We introduced two new solvent-free systems here 
based on non-toxic and renewable resources for the conversion of L-sorbose.  
 
 
 
 
 
 
 
Scheme 10 Synthesis of HMF 8 from L-sorbose 3 in a choline chloride melt.  
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Experimental 
General. Commercial reagents and starting materials were purchased from Aldrich, 
Fluka or Acros and used without further purification. Flash chromatography was 
performed on silica gel (Merck silica gel Si 60 40-63 μm); products were detected by 
TLC on aluminium plates coated with silica gel (Merck silica gel 60 F254, thickness 
0.2 mm) and visualised with 10% H2SO4 or KMnO4 staining solution. Melting points 
were determined with Optimelt MPA 100 and are uncorrected. NMR spectra were 
recorded with Bruker Avance 300 (1H: 300.1 MHz; 13C: 75.5 MHz; T=300 K), Bruker 
Avance 400 (1H: 400.1 MHz; 13C: 100.6 MHz; T=300 K) and Bruker Avance 600 Kryo 
(1H: 600.2 MHz; 13C: 150.9 MHz; T=298 K) instruments. Chemical shifts are reported in 
δ/ppm relative to the external standards and coupling constants J are given in Hz. 
Abbreviations for the characterisation of the signals: s = singlet, d = doublet, t = triplet, m = 
multiplet, bs = broad signal, dd = double doublet. The relative number of protons is 
determined by integration. Error of reported values: chemical shift 0.01 ppm (1H NMR), 
0.1 ppm (13C NMR), coupling constant 0.1 Hz. The used solvent for each spectrum is 
reported.  
Mass spectra were recorded on a ThermoQuest Finnigan TSQ 7000 LC/MS 
spectrometer (low resolution), high resolution spectra (HRMS) on an Agilent Tech 6540 
UHD Accurate Mass Q-TOF LC/MS and with Finnigan MAT TSQ 7000 (ESI) 
spectromter, IR spectra with a Bio-Rad FT-IR-FTS 155 spectrometer and UV/VIS spectra 
with a Cary BIO 50 UV/VIS/NIR spectrometer (Varian). Optical rotation was 
determined with Krüss optronic P8000T. 
N-(1,3,4,5-Tetra-O-acetyl-L-sorbopyranosyl)urea (7) 
L-Sorbose (0.6 g, 3.3 mmol), urea (1.4 g, 26.7 mmol) and NH4Cl (0.2 g, 3.7 mmol) were 
heated in a 10 mL reaction flask at 80 °C until a clear melt was formed. Amberlyst 15 
(150 mg) was added and the reaction was stirred for 1.5 h at that temperature. 
Methanol was added, solids filtered off and the solvent evaporated. Then, 6 mL (5.8 g, 
74.3 mmol) of pyridine and 3.5 mL of Ac2O (3.8 g, 37.0 mmol) were added to the 
mixture and the mixture was first stirred for 1 h in the ultra-sound bath and then over 
night at room temperature without sonication. The reaction was stopped by pouring 
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the solution into saturated NaHCO3 solution. The aqueous phase was extracted three 
times with CH2Cl2. The combined organic layers were washed twice with 2N HCl, 
twice with water and were finally dried over MgSO4 and evaporated. The pure product 
was crystallised from ethyl acetate affording a colourless powder (0.215 g, 0.55 mmol, 
16%). 
1H-NMR (300 MHz, CDCl3): δ [ppm] = 2.02, 2.04, 2.08, 2.10 (s, 12 H, OAc), 3.75 (dd, 
1 H, H-6), 4.01 (dd, 1H, 3J(H-5, H-6’) = 5.91 Hz, H-6’), 4.03 (dd, 1H, 2J(H-1, H-1’) = 12.36 
Hz, 166.24 Hz, H-1), 4.58 (dd, J1=12.33 Hz, J2=166.24 Hz, 1H, H-1’), 5.00-5.09 (m, 1H, 
H-5), 5.24 -5.40 (m, 5H, H-3, H-4, urea); 13C-NMR (75 Hz, CDCl3): δ [ppm] = 20.5, 20.6, 
20.5, 20.7 (CH3-Ac), 59.9 (C-5), 62.0 (C-1), 68.3 (C-4), 69.0 (C-5), 70.4 (C-3), 85.3 (C-2), 
156.6 (urea), 168.6, 169.8, 170.1, 170.2 (C=O, Ac);  
1H-NMR (600 MHz, CDCl3): δ [ppm] = 2.01, 2.04, 2.07, 2.10 (4×s, 4×3H, OAc), 3.74 
(“dd”, 2J(H-6ax, H-6eq) = 10.98 Hz, 3J(H-6ax, H-5) = 10.98 Hz, 1 H, H-6ax), 4.00 (dd, 3J(H-5, 
H-6’) = 5.91 Hz, 2J(H-6ax, H-6eq) = 11.07 Hz, 1H, H-6eq), 4.04 (d, 1H, 2J(H-1, H-1’) = 
12.37 Hz, H-1), 4.58 (d, 2J(H-1, H-1’) = 12.37 Hz, 1H, H-1’), 5.02-5.06 (m, 1H, H-5), 5.26 
(d, 3J(H-3, H-4) = 9.87 Hz, 1H, H-3), 5.35 -5.38 (m, 2H, H-4, urea); 13C-NMR (75 Hz, 
CDCl3): δ [ppm] = 20.5, 20.6, 20.6, 20.7 (CH3-Ac), 59.8 (C-5), 62.0 (C-1), 68.3 (C-4), 69.0 
(C-5), 70.4 (C-3), 85.3 (C-2), 156.7 (urea), 168.6, 169.8, 170.1, 170.2 (C=O, Ac); FT-IR 
(ATR): v [cm-1] = 3487, 3458, 3341, 1753, 1744, 1697, 1665, 1620, 1614, 1591, 1564, 1547, 
1535, 1441, 1433, 1377, 1371, 1275, 1229, 1211, 1138, 1103, 1061, 1032, 908; MP: 192 °C. 
ESI-MS: m/z (%) = 407.9 (MNH4+, 100), 431.9 (MH+ +MeCN, 37), 390.9 (MH+, 15). 
[ ]20Dα = -37.395 (c 1.000, chloroform) (α-anomer) (literature 143: [ ] 5.23Dα = -34.4 (c 0.973, 
chloroform). 
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Synthesis of HMF 
L-Sorbose (0.4 g, 2.2 mmol) and choline chloride (0.6 g, 4.3 mmol) were heated in a 
10 mL reaction flask at 80 °C until a clear melt was formed. Amberlyst 15 (150 mg) was 
added and the reaction was stirred at that temperature. After 1.5 h, water was added, 
solids were filtered off and the solution was extracted three times with ethyl acetate. 
The organic layer was dried over Na2SO4 and the solvent was evaporated to obtain the 
product (0.103 g, 0.8 mmol, 24%). The 1H-and 13C-NMR data were concordant with 
those in literature.149  
 
NOE spectrum for N-(1,3,4,5-Tetra-O-acetyl-L-sorbopyranosyl)urea (7) 
The NH/H-6ax and NH/H-1 NOE contacts in the α-conformation are clearly observed. 
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5. Base-, metal-, and photo catalysis in carbohydrate melts 
To establish new methods in order to convert carbohydrates in the melt, the effect of 
different chemical catalysts on sugar melts should be investigated. As no new 
discoveries were received from basic, metal, and photo catalysis, the observations will 
shortly be summarised. 
The effects of homogeneous and heterogeneous and inorganic and organic base 
catalysts (e.g. metal oxides and carbonates; triethylamine, DBU, (-)-sparteine) on 
glucose-urea-NaCl (6:3:1, wt:wt:wt) and glucose-choline chloride (2:3, wt:wt) melts 
were examined. Mainly, decomposition of the carbohydrate and the formation of 
complex mixtures due to Maillard reactions were observed. Using choline chloride 
melts, glucose underwent the Lobry-de Bruyn-van Ekenstein transformation, resulting 
in a mixture of glucose, mannose, and fructose.  
Metal catalysts were applied to achieve selective oxidation of glucose to glucuronic 
acid. A variety of oxidations conditions (e.g. KMnO4, Pt/O2, RuO2/NaIO4) were tried in 
glucose-urea-NaCl (6:3:1, wt:wt:wt), mannose-DMU (3:7, wt:wt), and sorbitol-urea-
NH4Cl, melts (7:2:1, wt:wt:wt). The formation of oxidation product was not obtained; 
glucosyl urea, complex reaction mixtures or no conversion of the carbohydrate were 
observed instead.  
To trigger radical or fragmentation reactions, four different low melting glucose 
mixtures with urea, dimethylurea, ethylene urea, or choline chloride as second 
component, were irradiated in the presence of photocatalysts (e.g. TiO2, Ru(bpy)3]Cl2, 
fluorescein, riboflavinetetraacetate). Under these conditions, the starting material 
glucose was recovered accompanied by glucosyl urea if the catalyst was acidic 
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6. Süße Chemie zum Dahinschmelzen - Kohlenhydrat-basierte 
Medien als alternative Lösungsmittel und zur Umsetzung 
von Zuckern  
 
 
Die Chemie der Zukunft wird notwendigerweise auf nachwachsende Rohstoffe als 
Ausgangsmaterial zurückgreifen müssen. Kostengünstige, kohlenhydratbasierte 
Schmelzen nutzen bereits nachwachsende Rohstoffe und stellen eine unkonventionelle 
Alternative zu erdölbasierten Medien dar. Physikalisch-chemische Eigenschaften, die 
Verwendung der Schmelzen als Lösungsmittel und die Umsetzung des Kohlenhydrat-
Anteils werden vorgestellt. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C. Ruß, B. König 
„Süße Chemie zum Dahinschmelzen“, GIT Labor Fachz., 2011, 55, (12), 836-837. 
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Einleitung 
Ein seit Jahren bekanntes und in letzter Zeit immer akuter werdendes Problem ist die 
zunehmende Verknappung der fossilen Ressource Erdöl. Steigender Verbrauch bei 
schwindenden Reserven erfordert eine langfristige und nachhaltige Alternative. Auch 
die Synthesechemie basiert zum großen Teil auf Erdöl als Rohstoff. Deshalb sind 
erneuerbare und umweltfreundliche Produkte und Prozesse zwingend erforderlich.150  
Kohlenhydrate sind attraktive Ausgangsverbindungen für die Herstellung von 
Feinchemikalien, da sie eindeutig den größten Anteil an jährlich erzeugter Biomasse 
stellen. Im Gegensatz zu fossilen Kohlenwasserstoffen, die durch Synthese 
funktionalisiert werden, müssen die komplexen Naturstoffe de- oder 
umfunktionalisiert werden. Bis jetzt ist in diesem Bereich das Potential der Chemie 
nicht ausgeschöpft und noch viel Forschungsarbeit zu leisten. Dazu tragen die von uns 
entwickelten Zuckerschmelzen bei. 
Physikalisch-chemische Eigenschaften der Zuckerschmelzen 
Jeder Hobbykoch weiß, dass beim Erhitzen des Haushaltszuckers Saccharose Karamell 
entsteht, im schlimmsten Fall Kohlenstoff. Will man allgemein Zucker ohne Zersetzung 
schmelzen ist dies durch die Mischung mit einer zweiten Komponente möglich. Durch 
die zweite Komponente werden Wasserstoffbrücken zwischen Zuckermolekülen 
aufgebrochen und so die Schmelzpunkte beider Substanzen erniedrigt. Infolgedessen 
ist der Zucker bereits bei 65 - 85 °C ohne zusätzliches Lösungsmittel flüssig. Außerdem 
kann durch die Zugabe von Salzen, wie z.B. NaCl, CaCl2 oder NH4Cl der 
Schmelzpunkt der Mischung weiter abgesenkt werden. So liegt der Schmelzpunkt von 
Glucose bei ca. 150 °C, der von Harnstoff bei 133 °C. Die Mischung aus Glucose, 
Harnstoff, NaCl (6:3:1, Massenverhältnis) schmilzt dann bei 78 °C. Die Stabilität der 
Zuckerschmelzen ist bis 120 °C gewährleistet; oberhalb dieser Temperatur können 
Zuckerabbaureaktionen stattfinden. Außer Glucose können auch andere Zucker, 
Zuckeralkohole oder Zitronensäure verflüssigt werden. Eine Schmelze aus Sorbitol, 
Harnstoff, Ammoniumchlorid (7:2:1, Massenverhältnis) ist immerhin bis 220 °C stabil.17 
Als zweite Komponente wurden neben Harnstoff und dessen Derivaten auch Imidazol, 
Malonsäure oder Cholinchlorid erfolgreich eingesetzt. Deren unterschiedliches Säure- 
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Basen-Verhalten ändert auch den pH-Wert der Schmelze. Dadurch kann der pH-Wert 
in einem Bereich von pH 3 bis 10 eingestellt werden.67 Werden Rohmaterialien 
verwendet, ergibt sich ein sehr geringer Wassergehalt von ca. 1.3%, der durch 
Trocknung im Vakuum auf 0.07% noch weiter reduziert werden kann. Zudem 
zeichnen sich die Schmelzen, wie auch ionische Flüssigkeiten, durch einen geringen 
Dampfdruck aus (1.2 · 10-1 mbar bei 70 °C).18 Soll die Schmelze als alternatives 
Lösungsmittel verwendet werden, ist die Polarität des Mediums von Bedeutung. 
Deshalb wurde die Polarität der süßen Lösungsmittel im Vergleich zu konventionellen 
polaren organischen Lösungsmitteln durch solvatochrome Farbstoffe wie Nile Red und 
Reichardt’s dye bestimmt. Derartige als Polaritätssonden eingesetzte Farbstoffe ändern 
ihre Farbe in Abhängigkeit von der Polarität des umgebenden Mediums. Da die 
Schmelzen in etwa so polar sind wie DMF, DMSO und Ethylenglykol, wurden darin 
verschiedene organische Reaktionen durchgeführt. So wurden die erforderlichen 
polaren Lösungsmittel in der Stille Reaktion, der Suzuki-Kupplung (Abb. 1a) oder 
Diels-Alder-Reaktion (Abb. 1b) durch die Schmelzen ersetzt. Nahezu quantitative 
Ausbeuten sprechen für den Erfolg des Konzepts.17-19 Die Schmelzen haben außerdem 
den Vorteil, dass die Aufarbeitung vereinfacht wird. Nach Zugabe von Wasser setzt 
sich entweder eine organische Phase mit den Produkten ab oder die Produkte fallen 
bereits aus und können dann abfiltriert werden. Ein weiterer Aspekt macht die 
Zuckerschmelzen zu einem interessanten Medium: die Hauptbestandteile sind chiral. 
Daher kann man sich vorstellen, dass die Chiralität des Lösungsmittels einen Einfluss 
auf die Stereoselektivität von Reaktionen haben könnte. Jedoch wurde weder bei der 
Diels-Alder-Reaktion (Abb. 1b), noch bei der katalytischen Hydrierung von 
1-Acetamidozimtsäure (Abb. 1c) eine nennenswerte Stereoinduktion festgestellt.17, 18  
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Konversion von Kohlenhydraten in der Schmelze 
Die bemerkenswert hohen Zuckerkonzentrationen von ca. 1 - 3 mol/l in den 
Mischungen ‒ das kann einem Zuckeranteil von bis zu 50% entsprechen ‒ machen 
diese für die chemische Umsetzung der verflüssigten Kohlenhydrate in 
Feinchemikalien interessant. 
Ein derzeit viel diskutierter Synthesebaustein ist 5-Hydroxymethylfurfural (5-HMF), 
da er aus verschiedenen Kohlenhydraten gewonnen werden kann.147 Dieses wird auch 
als potentieller klimaneutraler Rohstoff für Treibstoffe und Chemikalien angesehen. 
Die Verbindung 5-HMF entsteht beim Erhitzen von Kohlenhydraten durch Abspaltung 
von drei Wassermolekülen und Ausbildung des heteroaromatischen Systems. Dieser 
Prozess wurde im Arbeitskreis König gezielt in einer Cholinchlorid-Kohlenhydrat 
Schmelze mit verschiedenen sauren Katalysatoren herbeigeführt.67 Nach 30 Minuten 
Reaktionszeit bei 100 °C konnte mit D-Fructose und para-Toluolsulfonsäure eine gute 
Ausbeute von 67% erzielt werden (Abb. 2a). In einem ähnlichen Verfahren wurde 5-α-
D-Glucosyloxymethylfurfural (GMF), die glucosylierte Variante von 5-HMF, aus 
Isomaltulose durch gezielte Dehydratisierung des Fructosylteils hergestellt (Abb. 2b).68 
Dabei wurden mit ZnCl2 als Katalysator ebenfalls gute Ausbeuten von bis zu 52% 
erzielt. Klare Vorteile beider Methoden sind, dass auf problematische und teure  
 
.  
Abb. 1 Die niedrig schmelzenden Zucker-Harnstoff-Mischungen dienten als Lösungsmittel für 
a) die Suzuki-Kupplung, b) Diels-Alder-Reaktion und c) die katalytische Hydrierung von 
1-Acetamidozimtsäure. 
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Lösemittel, wie z.B. DMSO, verzichtet werden kann und eine kontinuierliche 
Prozessführung in flüssiger, hochkonzentrierter Schmelze prinzipiell möglich ist. 
Des Weiteren wurden in der Schmelze in einer einstufigen Reaktion Glycosylharnstoffe 
hergestellt.135 Dabei addiert Harnstoff unter Abgabe von Wasser am C-1 Atom des 
Saccharids und es wird selektiv das stabilere β-Anomer gebildet (Abb. 2c). Zum ersten 
Mal wurde Glucosylharnstoff im Jahr 1900 von Schoorl beschrieben106 und findet 
seitdem breite Anwendung, z.B. als Spezialdünger oder als Teil biologisch aktiver 
Moleküle. Nach einer verbesserten Vorschrift konnte in wässriger Lösung nach vier 
Tagen Reaktionszeit bei 75-80 °C eine maximale Ausbeute von 53% erreicht werden. 
Benutzt man aber eine Zucker-Harnstoff-Schmelze, so kann bei 80 °C schon nach zwei 
Stunden Reaktionszeit in Gegenwart des heterogenen, sauren Katalysators 
Amberlyst 15 eine Ausbeute von 81% des gewünschten Produkts erzielt werden. Auf 
diese Weise lassen sich Monosaccharide, wie z.B. Mannose, Galactose und 
2-Deoxyglucose zu verschiedenen Harnstoffderivaten umsetzen.  
Nicht nur Kohlenhydrate lassen sich in der Schmelze umsetzen. In ähnlicher Weise 
können pharmazeutisch interessante Grundstrukturen mittels einer 
Mehrkomponentenreaktion durch säurekatalysierte Kondensation von Aldehyden und 
β-Ketoestern mit Harnstoff in exzellenten Ausbeuten synthetisiert werden.151 Dabei 
 
Abb. 2 a) Umsetzung von Kohlehydraten zu 5-HMF, b) Gewinnung von GMF aus Isomaltulose,
c) Synthese von Glycosylharnstoffen in der Zucker-Harnstoff-Schmelze. 
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spielte die Weinsäure-Dimethylharnstoff-Schmelze eine dreifache Rolle: als 
Lösungsmittel, Katalysator und Reaktand. 
Zusammenfassung 
Mit den Zuckerschmelzen steht uns ein ungewöhnliches und vielseitiges 
Reaktionsmedium zur Verfügung. Die stabilen und nichtflüchtigen Mischungen haben 
die Vorteile, dass sie nicht toxisch sind, aus erneuerbaren Ressourcen gewonnen 
werden können, leicht verfügbar und biologisch abbaubar sind. Durch ihre hohe 
Polarität können sie konventionelle Lösungsmittel wie DMF oder DMSO ersetzen. Der 
hohe prozentuale Zuckeranteil macht sie außerdem für die milde, effiziente und 
lösungsmittelfreie Konversion von Kohlenhydraten attraktiv. 
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7. Conclusion 
In the course of this project, acidic, basic, metal, and photo catalysts were applied to 
carbohydrate melts. We aimed to find chemical reactions converting carbohydrates in a 
selective and efficient way into fine chemicals in this screening process. 
The present study revealed that under basic conditions carbohydrates isomerise via 
well-known keto-enediol intermediates which are in equilibrium. Besides, observed 
decomposition reactions were also unselective. The addition of amines led to random 
Maillard products. Caramelisation products occurred constantly, especially at high 
temperatures. Furthermore, we could show that carbohydrates were not converted by 
applying metal catalysis, with the focus on oxidation reactions, or photo catalysis. 
Often, glucosylurea was formed during the reaction.  
Acid catalysed reactions provided the most promising results. In choline chloride 
melts, acids catalyse the elimination of water molecules which leads to furfural 
derivatives, important organic platform chemicals. We illustrated the synthesis of 
5-hydroxmethylfurfural (5-HMF) from L-sorbose and 5-(α-D-
glucosyloxymethyl)furfural (GMF) from isomaltulose. 
In general, glycosylureas are produced in sugar-urea melts from different aldohexoses 
as well as from ketohexoses under acidic conditions. They are remarkably stable and 
are stereoselectively formed in high yields and short reaction times. Slightly acidic 
conditions are sufficient to make them the preferred product. Thus, we could improve 
existing syntheses of glycosylureas by implementing a method using environmentally 
benign bulk chemicals without the need of a solvent. Accordingly, reactions times were 
reduced and yields were increased. 
Summing up, we concluded that sugars show similar reaction behaviour in melts as in 
solution.  
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8. Zusammenfassung 
Im Verlauf dieses Projektes wurden Säure-, Basen-, Metall- und Photokatalysatoren 
hinsichtlich ihrer Wirkung auf Kohlenhydrat-Schmelzen untersucht. Unser Ziel war es 
in einem „Screening“-Verfahren chemische Reaktionen zu finden, in denen 
Kohlenhydrate, speziell Monosaccharide, selektiv und effizient zu Feinchemikalien 
umgesetzt werden. 
Unter Basen-, Metall- und Photokatalyse verliefen die Reaktionen unselektiv, 
weswegen sie hier nur kurz zusammengefasst werden. Basische 
Reaktionsbedingungen führten zu einer Epimerisierung von Glucose, die im 
Gleichgewicht mit Mannose und Fructose (und anderen epimeren Hexosen) vorlag. 
Ebenfalls unter basischen Bedingungen auftretende Abbaureaktionen wurden auch in 
der Schmelze beobachtet, waren aber nicht selektiv. Eine Vielzahl von 
Maillardprodukten entstand nach der Zugabe von Aminen. Bei den meisten 
Reaktionsansätzen entwickelten sich Karamellisierungsprodukte, insbesondere bei 
hohen Temperaturen. Des Weiteren wurden die Kohlenhydrate in Anwesenheit von 
Metall- oder Photokatalysatoren oft nicht umgesetzt; häufig war Glucosylharnstoff das 
bevorzugte Produkt. Vielversprechende Ergebnisse wurden unter sauren Bedingungen 
erhalten. In Cholinchlorid-Schmelzen wurden säurekatalysiert nach Abspaltung von 
Wassermolekülen Furfural-Derivate, wichtige organische Bausteine, erhalten. Auf 
diese Weise wurde 5-Hydroxymethylfurfural (HMF) aus verschiedenen 
Kohlenhydraten und 5-(α-D-Glucosyloxymethyl)furfural (GMF) ausgehend von 
Isomaltulose hergestellt. In Zucker-Harnstoff-Schmelzen war die Bildung von 
Glycosylharnstoffen, ausgehend von Hexosen und auch Ketosen, nach sehr kurzen 
Reaktionszeiten in hohen Ausbeuten auffallend. Glucosylharnstoff war oft das 
Hauptprodukt bei versuchten Oxidationsreaktionen und Photoreaktionen. Schwach 
saure Bedingungen sind offenbar ausreichend, dass dieser das bevorzugt gebildete 
Produkt ist.  
Zusammenfassend zeigten unsere Versuche, dass die Zucker in der Schmelze ein 
ähnliches Reaktionsverhalten aufweisen wie in Lösung. 
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II. MELANOMA INHIBITORY ACTIVITY (MIA) PROTEIN 
INHIBITORS FOR THE TREATMENT OF MALIGNANT 
MELANOMA  
Introduction and Goals 
Over the last three decades, the incidence of malignant melanoma, a very aggressive 
type of skin cancer, increased drastically.152 The survival rate of this malignant tumor 
of transformed melanocytes is extraordinarily poor once the melanoma has 
metastasised.152 The formation of metastases already occurs at early stages of the 
disease and is further accompanied by uncontrollable growth of the highly invasive 
tumor. 
Currently, the main therapeutic strategies are surgical resection and systemic 
chemotherapy, but they are not always effective.153 It is therefore of utmost importance 
to develop new strategies for the treatment of malignant melanoma. New strategies 
involve immunotherapy and molecular targeting, e.g. inhibition of mutated BRAF and 
RAF kinase family members.152  
Since the identification of melanoma inhibitory activity (MIA) protein in the early 
1990s, it was shown to play a key role in development, progression and metastasis of 
malignant melanoma cells and was therefore assessed as interesting target to regulate 
the formation of metastases.154, 155 Importantly, MIA protein, an 11 kDa protein is only 
expressed in malignant melanoma cells and early-phase differentiating chondrocytes, 
but not in normal melanocytes.156, 157 In tumor cells secreted MIA inhibits the 
attachment of melanoma cells to the extracellular matrix (ECM) components like 
fibronectin, laminin, and tenascin in vivo.158-160 These ECM structures are responsible for 
cellular adhesion (cellular ‘glue’) and interconnect the cells. The blocking of these 
binding sites by MIA protein reduces the cell matrix contacts, and thus enables the cell 
to migrate, invade and, finally, metastasise.  
The three-dimensional structure of MIA protein was determined by multidimensional 
nuclear magnetic resonance (NMR) spectroscopy and X-ray crystallography 
techniques.161-165 Further studies revealed that self-assembly of MIA protein is crucial 
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for functional activity; the dimers are assembled by head-to-tail orientation.165, 166 By 
inhibiting the dimerisation and/or by inducing the dissociation of functionally active 
MIA dimers by e.g. small molecules, tumor cell invasion and formation of metastases 
could be reduced. Moreover, side effects of conventional chemotherapy targeting all 
fast dividing cells should be reduced as MIA protein is only expressed in malignant 
melanoma and differentiating chondrocytes. Such antimetastatic agents (which inhibit 
the dimerisation of MIA protein) would be a powerful tool in treatment of malignant 
melanoma.  
A heterogeneous transition metal-based fluorescence polarization (HTFP) assay has 
been established to selectively screen for MIA dimerisation inhibitors. In this screening 
assay a dodecapeptide with the sequence Ac-FHWRYPLPLPGQ-NH2, designated as 
AR71, was identified as particularly potent. NMR spectroscopy revealed that AR71 
binds to the dimerisation domain of MIA protein.167, 168 Furthermore, the inhibitory 
potential of this dodecapeptide was confirmed in in vitro and in vivo studies. After 
daily i.v. injections of AR71 into a mouse melanoma model, strongly reduced numbers 
of metastases were observed in the mice.167, 168 After testing both mutated and truncated 
peptide sequences derived from AR71, hexa-, tetra-, and even tripeptides, were shown 
to inhibit MIA dimerisation much better than AR71.165 Therefore, we focused our 
investigations on the following sequences: WWW, WHW, WHF, and furthermore 
FHWH and FHWRYP. 
The major drawback of peptidic drug candidates is that the mammalian system has 
developed efficient barriers to restrict the intrusion of foreign macromolecules.169 As a 
consequence, drug molecules are removed from the systemic circulation by these 
protective mechanisms and a therapeutic effect might not be achieved due to low 
concentrations at the target. The first barrier comprises proteolytic enzymes that 
degrade the protein. They are widely distributed over the human body and show their 
highest activity and the highest occurrence particularly in the intestinal tract.169 
Secondly, proteins have to overcome different absorption barriers, most important of 
these barriers is the passing over biological membranes.169 Moreover, proteins are 
rapidly removed from the circulation by the liver and kidneys. To summarise, peptides 
exhibit a low bioavailability due to their poor pharmacokinetic properties: small  
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proteins are rapidly renally cleared from the bloodstream. Their short in vivo half-lifes 
(< 30 min) usually entails a frequent application.170 Although oral application is most 
convenient, a parenteral delivery, e.g. i.v. injection, is necessary for this substance class 
to avoid the gastrointestinal tract and achieve high plasma concentrations.171  
Different strategies are proposed to increase the bioavailability by improving 
pharmacokinetic properties (absorption, distribution, metabolism, extraction, 
toxicology (ADMET)) of peptide and protein drugs. We pursued two strategies in this 
work: the modification of the molecular structure to enhance the stability against 
enzymatic degradation and to increase the permeability across biological membranes. 
The second approach utilises the versatile tool of drug formulation, in particular 
sustained release systems.169, 172 
We therefore modified the chemical structure of the lead peptide systematically: the 
amide bond in the peptide backbone was N-methylated (chapter 9.1) and the amide 
moiety was replaced by a pseudo-isosteric group (peptoid, chapter 9.2). Additionally, 
head-to-tail-cyclisation (chapter 9.3) of the lead structures should give more 
information about the bioactive conformer and structure-activity-relationships. The 
functional activity of the synthesised compounds was determined by HTFP assay, 
Western Blot analysis, and Boyden chamber invasion assay. 
Equally important, PEGylated peptides (chapter 10.1), a lipid implant (chapter 10.2) 
and hydrogels (chapter 10.3) for sustained release were developed and the in vitro 
release kinetics were investigated.  
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9. Melanoma inhibitory activity (MIA) protein inhibitors – 
Synthesis and biological testing  
 
 
MIA protein is an important factor in the formation of metastases of the malignant 
melanoma. Highly potent MIA inhibitors would be a powerful tool in the treatment of 
this type of skin cancer. Known MIA protein inhibitors are small peptidic molecules. 
To increase their in vivo stability, N-methylated 1-3 and cyclic derivatives 7-11, as well 
as peptoids 4-6, were synthesised and tested by in vitro methods: the heterogeneous 
transition metal-based polarisation (HTFP) assay and Western Blot analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All compounds assembled by solid phase synthesis were synthesised by C. Ruß. The 
bifunctional poly(ethylene glycol) linker was kindly provided by Dr. Florian Schmidt, 
University of Regensburg. 
The test assays of the biological activity were performed by Dr. Alexander Riechers, 
Institute of Molecular Pathology, Regensburg.  
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Introduction 
A common approach to obtain more stable and bioactive peptides is to gradually 
transform the peptide into derivatives with a less peptidic character, termed peptide 
mimetics or also peptidomimetics. They are defined as derivatives of a (biologically 
active) peptide whose structural features should be analogous to the original peptide 
sequence. Moreover, the functional activity should be preserved or improved.173, 174 The 
interested reader is referred to a small selection of excellent review articles covering 
this topic.173, 175 
With this study, we aimed to get further insight into the structure-activity relationship 
of MIA protein inhibitors; but more importantly, we wanted to increase the metabolic 
stability of the peptides. To this end, we transformed known effective MIA protein 
inhibitors into peptidomimetics. 
Results and Discussion 
9.1 N-methylation of peptide backbone 
A simple and efficient method nature uses to increase the stability against proteases 
and the membrane permeability (due to a higher lipophilicity) is the N-methylation of 
the amide moiety in the backbone of peptides.176, 177 An additional substituent at the 
N-atom influences not only the pharmacological properties, but also the conformation 
of the molecule. Steric hindrance creates more rigid molecules with less conformational 
freedom favouring an extended (trans) conformation.178, 179  
Alkylation of primary amines with alkyl halides and dialkyl sulfates often generates 
undesired tertiary amines and/or (quarternary) ammonium salts, as the reaction 
product is more nucleophilic than the starting material and reacts preferentially with 
the alkylating agent.180 To circumvent this problem, the N-methylated peptides were 
synthesised by an optimised solid-phase method published by Biron et al.181 which is 
based on a three-step procedure developed by Miller and Scanlan (Scheme 11).182 
Succinctly, the free amino group is protected and activated by an 
o-nitrobenzenesulfonyl group (o-NBS) which is followed by direct methylation 
(pathway A) or Mitsunobu reaction (pathway B). After deprotection, the coupling step 
was performed twice to complete the coupling of the sterically hindered N-atom.  
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At first, an N-methyl scan of the tripeptides WHW, WHF, and WWW was carried out 
along the backbone of the peptides (Figure 4). Therefore, single amide bonds were 
systematically methylated at the N-atom. Accordingly, two derivatives per sequence 
were synthesised to cover all expedient sites of methylation.  
9.2 Peptoids (N-alkylated glycines) 
Another way to replace the amide bond in the backbone is the transformation into 
peptoids (or N-alkylated glycines). This class of compounds is very versatile and easy 
to synthesise by a solid-phase submonomer synthesis protocol which will be described 
below (Scheme 12).183 Peptoids are similar to retro-inverso peptidomimetics; the side 
chain which is normally attached to the α-C atom is shifted to the achiral amide 
nitrogen. Stereochemical information is lost as the backbone becomes also achiral. 
Another consequence is a gain of flexibility. Similar to N-methylation, the absent amide 
proton changes the stabilisation of the secondary structure of the peptoid oligomer by 
hydrogen bonding in comparison to the original peptide. Secondary structures, like 
α-helices, can then be induced by the introduction of chiral side chains.184 These 
 
Scheme 11 Procedure of N-methylation on solid phase (according to literature181). 
 
Figure 4 Structures and yields of the synthesised N-methylated MIA inhibitors 1-3. 
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structural changes further increase the hydrophobicity of the peptoid, thus improving 
permeability across cell membranes185, 186 and enhancing protease resistance.187, 188 
The most common synthesis approach to peptoids was developed by Zuckermann et 
al. in 1992 and is based on a submonomer solid-phase synthesis (Scheme 12).183 Briefly, 
the oligomers are assembled from the C- to the N-terminus in two repetitive steps. The 
first step is a (DIC)-mediated acylation with chloro- or bromoacetic acid. In the second 
step, the halide is substituted by a primary amine.  
The peptoids synthesised in this work had the same sequence of side chain residues as 
the original tripeptides WHW, WHF, and WWW (Figure 5). In addition to the 
compounds with free N-terminus, in a set of derivatives the N-terminus was acetylated 
to simulate the natural continuous amide bonds in the backbone of proteins. 
9.3 Cyclisation 
Naturally occurring macrocycles are a complex, and highly interesting substance class. 
They protrude by their numerous and diverse biological activities and favourable 
pharmacological properties. The peculiarity of cycles lies in the unusual structural 
combination of rigidity and flexibility. Ring formation results in a pre-organisation of 
functional groups in the molecule. One consequence is that the loss of entropy is 
reduced on binding to a biological target and the binding event is energetically more 
 
Scheme 12 Synthesis of peptoids by the submonomer method on solid phase (according to
literature183). 
  
Figure 5 Structures and yields of peptoids 4-6. 4a-6a: free N-terminus, 4b-6b: acetylated 
N-terminus. 
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favourable. Furthermore, pharmacological stability against proteolytic or metabolic 
degradation improves the bioavailability distinctly.189 When the ring structure is pre-
organised in such a way that it matches the bioactive conformation, a highly potent 
ligand with high affinities and selectivities can be achieved.190  
These principles are also valid for cyclic peptides. The number of distinct 
conformations is notably reduced upon cyclisation of very flexible linear peptides.191, 192 
In addition, cyclic peptides are more resistant to exo- and endopeptidases. Although 
the macrocycles often do not abide to Lipinski’s “rule of five” (which states that poor 
absorption or permeation of a drug is more likely when there are more than 5 H-bond 
donors, 10 H-bond acceptors, the molecular weight is greater than 500 Da and the 
calculated Log P is greater than 5)193, they still expose drug like physico-chemical and 
pharmacological properties (like good solubility, lipophilicity, metabolic stability, 
bioavailability).190 The use of cyclic peptides in therapy is still limited, but a growing 
field. The difficulty in designing cyclic peptide mimics is to retain the biological 
activity after changing the structure. It is therefore advantageous to know the role of 
each amino acid.194  
Synthetically, linear peptides can be connected at four different sites: head-to-tail, side 
chain-to-tail, head-to-side chain, and side chain-to-side chain.191 Generally, 
intramolecular cyclisations work out best under high dilution, thus intermolecular 
reactions (like oligo- and polymerisation) are less prone to occur. To exploit the 
practical advantages of solid phase synthesis, we followed the strategy to use the 
trifunctional amino acid aspartic acid as anchor to the resin in the first step. 
Furthermore, the C-terminus must be protected orthogonally to the here applied 
standard Fmoc protocol, which is termed three-dimensional orthogonal strategy.195 The 
allyl group is especially suitable as it is stable against common acidic and basic 
conditions. For example, allyl carboxylates are readily removed in the presence of a 
soluble palladium catalyst (typically Pd(PPh3)4) while the allyl group is scavenged by a 
nucleophile.196 After assembling the linear precursor on the solid phase, the protecting 
groups at the C- and N-termini were removed; the peptide sequence was then cyclised 
in a head-to-tail manner and the product was finally cleaved from the solid support. 
Although a “pseudo-dilution effect”197 is described for reactions on solid phase, a resin 
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with especially low loading was chosen to avoid the formation of oligomers.198 We 
introduced a small ethylene glycol spacer into the cyclic tripeptides (Scheme 13, n = 2) 
to reduce the ring strain, also enabling a regulation of the ring size. Furthermore, 
previous results showed an enhancement of activity of PEGylated peptides, (see 
chapter 10.1). The linker might also increase solubility and stability of the peptide. In 
addition to tripeptides, cyclic derivatives of the sequences FHWH and FHWRYP, also 
highly potent MIA inhibitors, were synthesised (Figure 6). The coupling reagent 
propane phosphonic acid anhydride (®T3P) was used for the crucial cyclisation step.199 
T3P is a mild and non-toxic reagent which is easy to handle. Amide bond formation 
proceeds with high yields and low epimerisation.200 The best results were obtained 
applying the method patented by Mollenkopf (T3P, DIPEA, 2 d, rt).201  
All steps of synthesis are depicted in Scheme 13. Initially, the Fmoc-Asp-OAlloc was 
anchored to the solid phase. Subsequently, the amino acids were coupled by standard 
Fmoc protocol. When only three amino acids were attached to the anchor, an ethylene 
 
 
 
 
 
 
 
 
Scheme 13 Synthesis of cyclic peptides 7-11 on solid phase using Fmoc-Asp-OAlloc as 
trifunctional anchor. Into cyclic peptides derived from tripeptide sequences WHW, FWH, and 
WWW (n = 2), an ethylene glycol linker was introduced. For deprotection, ring closure, and
cleavage the same procedures were used.  
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glycol linker was introduced by a double coupling step. After that step, the same 
conditions were used for all peptides. Before ring closure, first the Alloc group, then 
the Fmoc group at the amino terminus were removed. Lastly, the completed peptides 
7-11 were cleaved from the solid support (Figure 6). 
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Figure 6 Structures and yields of synthesised cyclic peptides 7-11. 7-9: derived from tripeptides 
containing an ethylene glycol spacer, 10-11: cyclic derivatives of tetra- and hexapeptides FHWH 
and FHWRYP, respectively. 
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9.4 A fast screening process was applied to find potential drug candidates 
Novel active compounds were assessed using different reliable methods. In the 
screening process, three assays were performed in successive order: 
1) Heterogeneous Transition Metal-based Fluorescence Polarization (HTFP) Assay 
2) Western Blot Analysis 
3) Boyden Chamber Invasion Assay  
The subsequent tests were only performed if the tested compound was significantly 
potent in the previous test. Using the HTFP assay, the activity was determined in 
relation to the original peptide AR71 which serves as reference, and to the blank value 
(MIA bound the well surface). Therefore, the most important information we obtained 
from this assay was, whether the inhibitory performance of the newly synthesised 
compounds was increased or reduced in comparison to AR71 (or the blank value). In 
some cases the compounds were auto-fluorescent and interfering with the HTFP assay; 
in these cases, the Western Blot was used instead.  
As the HTFP assay was especially developed by Riechers et al. to efficiently screen the 
biological activity of large libraries of potent MIA inhibitors, and most of the testing 
results are based on the outcome of the HTFP screening, the concept and the 
experimental setup will be outlined succinctly (Figure 7).202 
Biotinylated MIA protein is immobilised on a streptavidin-coated well plate. This 
protein binds the Ru(bpy)3-labelled MIA protein and forms dimers. In the absence of a 
competitive inhibitor Ru(bpy)3-labelled MIA protein is tethered to the well’s surface, 
dramatically increasing its apparent mass and slowing down rotational motion. This 
reduced molecular rotation results in an increase in fluorescence polarisation indicated 
by high values. In the presence of an inhibitor, the MIA protein is displaced from the 
immobilised MIA protein; the MIA dimers are cleaved. The newly formed inhibitor-
MIA protein complex can now freely rotate in solution and the polarisation P is 
decreased. Physically possible values for P are ranging from -⅓ to ½.203 Polarisation 
values are reported relative (P/P0) to the value of free Ru(bpy)3-labelled MIA in 
solution (P0 (in a well not treated with MIA-biotin). 
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Western Blot analysis 
For Western Blot analysis, MIA protein was pre-incubated with the potential 
inhibitors, before gel electrophoresis, blotting and immunodetection. In the presence of 
active compounds a dissociation of the MIA protein dimer was observed: the dimer 
bands were remarkably reduced compared to the control lane.  
Streptavidin
Biotin conjugated MIA Inhibitor
MIA
Luminescent transition
 metal label
free rotation 
in solution
 
Figure 7 Concept of HTFP Assay: The biotin conjugated MIA protein is immobilised on a 
streptavidin coated well plate. MIA binds the Ru(bpy)3-labelled MIA protein, forming dimers. 
In the absence of a competitive inhibitor Ru(bpy)3-labelled MIA protein is tethered to the well’s 
surface, dramatically increasing its apparent mass and slowing down rotational motion (left). In 
the presence of an inhibitor, the MIA protein is competitively displaced from the immobilised 
MIA (right). The newly formed inhibitor-MIA protein complex can now freely rotate in solution 
and the polarisation is decreased. 
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N-Methylation of peptide backbone 
Although N-methylation seemed a very promising strategy, the first screening step, the 
HTFP assay, showed that all methylated peptides 1-3 were less active than the 
reference AR71. The polarisation values are higher than those of AR71, comparable to 
the blank without inhibitor (Figure 8).  
Due to the low solubility of compounds 1b, 2a, and 2b, the used concentration was ⅕ 
of the usual concentration (1.6 μM instead of 7.8 μM). Consequently, different 
polarisation values were measured for AR71 in both assays. 
As the performance of the N-methylated peptides was mediocre, further testings were 
not carried out.  
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Figure 8 Results of the HTFP assay of N-methylated peptides 1-3. The compounds were less 
effective inhibitors than AR71; there is only a small difference from the blank value. Blank 
uncoated: free MIA Ru(bpy)3 protein in solution; Blank: MIA bound to another MIA protein on 
the surface. 
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Peptoids 
All N-alkylated glycines 4-6 were auto-fluorescent and therefore interfering with the 
HTFP assay. For this reason, this compound class was only investigated by Western 
Blot analysis. MIA protein dimers with a molecular weight of about 22 kDa were not 
significantly reduced; they also show an intensity which is comparable to the control 
lane containing only MIA protein without inhibitor (Figure 9).  
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Figure 9 Results of the Western Blot analysis for the peptoids 4-6. MIA dimers (22 kDa, right 
lane) are still formed in the presence of the compounds 4-6. 
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Cyclic peptides 
The HTFP assay showed that also the cyclic peptides 7-11 were less potent than AR71 
(Figure 10A) HTFP assay 7-9 (Figure 10B). Heptapeptide 11 could not be tested with 
this method as it was auto-fluorescent. The HTFP assay showed that the polarisation 
was comparable to the blank value without any inhibitor. These results were also 
confirmed by the Western Blot: the amount of dimers was similar to the untreated MIA 
protein (right). 
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Figure 10 Results of A) HTFP assay 7-9 (11 was auto-fluorescent and could not be measured) 
and B) Western Blot analysis of cyclic peptides 7-11. The compounds were less effective 
inhibitors than AR71; there is only a small difference from the blank value. MIA dimers (22 kDa, 
right lane) are still formed in the presence of the compounds 7-11. 
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Truncated and mutated peptide sequences derived from AR71 with up to twelve 
amino acids were discovered to inhibit the dimerisation of MIA protein, an important 
factor in metastasis of malignant melanoma. What kind of picture does literature give 
to imagine these protein-protein interactions between two (or more) MIA protein 
monomers on a molecular level? Such homodimers interact via their surface amino 
acids. So-called hot spots stabilise the dimeric complex by contributing most of the 
binding energy and are crucial for the affinity of the interaction.204, 205 These hot spots 
are clustered regions buried in the centre of the protein.204 Another characteristic 
feature of dimer protein-protein interfaces is that they expose structural properties of 
both, interior and exterior protein surfaces, but more similar to the exterior.206 The area 
of the interface contains, similar to other proteins, mostly non-polar side chains which 
are buried in the interior of the interface and polar and charged groups are prevalently 
found in the exterior.206, 207 Statistically, the amino acid composition in protein-protein 
interaction sites is enriched in tryptophane (21%), arginine (13.3%) and tyrosine 
(12.3%), while it is less likely to find leucine, methionine, serine, threonine and valine 
residues (less than 3%).208 In contrast to protein monomers, polar and charged residues 
play a significant role in the stabilisation of the protein assemblies by hydrogen bonds 
and salt bridges (larger percentage than in monomers).209  
With regard to MIA protein, NMR titration of MIA with AR71 revealed that the 
residues C17, S18, Y47, G66, D67, L76, W102, D103 and C106 of MIA protein are clearly 
involved in the binding at the interface. The interacting amino acids in the binding sites 
of MIA protein are mainly composed of hydrophobic and aromatic residues, followed 
by acidic and neutral residues, reflecting the above described picture of the possible 
binding mode. Another aspect underpinning this concept is that hydrophobic and 
aromatic amino acids predominate in the small peptidic inhibitors and seem to be 
crucial for the binding interaction.  
All synthesised candidates were less active than the parent compound AR71 and the 
unmodified peptides (showed a diminished activity compared to) which was shown in 
the initial screening test, the HTFP assay and the Western Blot analysis.  
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Certainly, the structural modifications altered the interaction with the target structure. 
A change of the ligand conformation might impede that the compound binds to the 
interacting area of the MIA dimers.  
Conformational changes are to be expected for N-methylated and cyclised peptides. 
Methyl groups are bulkier than an H-atom. They impose the side chain residues to 
adopt a certain conformation, preferably trans conformation, and also rigidify the 
molecule.177 Similarly, ring formation introduces conformational restraints and reduces 
the number of possible conformations. The cyclic peptides with a strongly restricted 
conformation did obviously not match the bioactive conformation.  
Possibly, the H-atom at the amide nitrogen plays an important role in peptide-MIA 
protein interactions, e.g. via hydrogen bonds, as both N-methyl and peptoids lack that 
moiety and both are less potent MIA protein inhibitors than the native parent peptides. 
Unexpectedly, ethylene glycol spacers did not improve solubility; on the contrary, the 
hydrophobicity of the molecules was increased.  
Conclusion 
Backbone modifications of known MIA inhibitory peptides were synthesised and 
tested for their ability to inhibit MIA dimerisation. N-methylation, cyclisation, and 
transformation to peptoids might have resulted in the desired enhanced metabolic 
stability, but also reduced the potency in comparison to the original inhibitors.  
We conclude that change of conformation and loss of an H-bond donor are the reasons 
for the mediocre activity. Although we gained more information on the structure 
activity relationship of the MIA inhibitors, a promising candidate was not found. The 
synthesis of more modified derivatives to find an active compound might be 
supplemented by computer-assisted methods, like docking studies. 
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Experimental 
General. Commercial reagents and starting materials were purchased from Aldrich, 
Fluka or Acros and used without further purification. Fmoc-protected amino acids 
were acquired from Iris Biotech GmbH; coupling reagents and resins from 
NovaBiochem (Darmstadt, Germany). The coupling agent T3P was a kind gift of 
Archimica, (Frankfurt/M, Germany). Mass spectra were recorded on a ThermoQuest 
Finnigan TSQ 7000 LC/MS spectrometer (low resolution), high resolution spectra 
(HRMS) on an Agilent Tech 6540 UHD Accurate Mass Q-TOF LC/MS and with 
Finnigan MAT TSQ 7000 (ESI) spectrometer. 
Analytical HPLC 
Column: Phenomenex Luna 3 um C18 (2) 100 A, 150 mm x 2.00 mm,  
Agilent 1100/1; G1312A Bin Pump, G1313A ALS; G1316A COLCOM, G1315B DAD, 
G1379 DEGASSER, G1321A FLD; software: ChemStation for LC 3D Systems Rev 
B.04.02 SP1; column temperature: 25 °C, FLD-A, ELS; Column temperature: 25 °C, 
FLD-A, ELS; UV detection at 220 nm, fluorescence detection: zero-order. Gradient: 
from 3% MeCN/H2O (0.0059% TFA) to 98% MeCN/H2O (0.0059% TFA) within 30 min. 
Flow rate: 0.3 mL/min, injection volume: 1 μL; 
Preparative HPLC 
Column: Phenomenex Luna 10 um C18(2) 100 A, 250 x 21.1 mm 
Agilent 1100 Series; Software: Chemstation for LC 3D Systems Rev. B03.02 
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Peptidomimetics 
Sequence: H-W-H-W(Me)-NH2 (1a) 
TFA: 0.059 %  
Yield: 8.1 mg, 52% 
HPLC (analytic): Rt = 12.135 min (DAD), 12.271 min (ELSD); LC/MS (ESI): m/z = 541.2 
(MH+) (Rt = 12.89 min, 100%); ESI: m/z = 291.5 (M+2H)2+ + MeCN (Rt = 9.77 min, 100%), 
541.1 (MH+)(83%); HPLC (preparative): Gradient (t (min), % B: (0, 3), (12, 37), (15, 95), 
(25, 95), Rt = 10.72 min; Empirical formula: C29H32N8O3, MW = 540.62 
Sequence: H-W-H(Me)-W-NH2 (1b) 
Yield: 6.3 mg, 42% 
HPLC (analytic): Rt = 8.122 min (DAD), 8.213 min (ELSD); LC/MS (ESI): m/z = 291.6 
(M+2H)2+ + MeCN (Rt = 6.90 min, 100 %), 541.2 (MH+) (39 %); ESI: m/z = 291.6 (M+2H)2+ 
+ MeCN (Rt = 4.17 min, 100 %), 541.1 (MH+)(23 %); HPLC (preparative): Gradient 
(t (min), % B: (0, 5), (12, 60), (14, 98), (22, 98), Rt = 6.61 min Empirical formula: 
C29H32N8O3, MW = 540.62 
Sequence: H-W-H-F(Me)-NH2  (2a) 
Yield: 5.9 mg, 41% 
HPLC (analytic): Rt = 8.067 min (DAD), 8.145 (ELSD) min; LC/MS (ESI): m/z = 502.1 
(MH+) (Rt = 5.73 min, 100%); ESI: m/z = 272.0 (M+2H)2+ + MeCN (Rt = 4.05 min, 100%), 
502.2 (MH+)(46%); HPLC (preparative): Gradient (t (min), % B: (0, 5), (12, 60), (14, 98), 
(22, 98), Rt = 6.61 min; Empirical formula: C27H31N7O3, MW = 501.58 
Sequence: H-W-H(Me)-F-NH2  (2b) 
Yield: 5.0 mg, 35% 
HPLC (analytic): Rt = 8.126 min (DAD), 8.213 (ELSD) min; LC/MS (ESI): m/z = 272.0 
(M+2H)2+ + MeCN (Rt = 6.14 min, 100%), 502.1 (MH+)(74%); ESI: m/z = 272.0 (M+2H)2+ + 
MeCN (Rt = 4.27 min, 100%), 502.2 (MH+)(20%); HPLC (preparative): Gradient (t (min), 
% B: (0, 5), (12, 60), (14, 98), (22, 98), Rt = 6.61 min; Empirical formula: C27H31N7O3, MW= 
501.58 
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Sequence: H-W-W-W(Me)-NH2 (3a) 
Yield: 3.4 mg, 21% 
HPLC (analytic): Rt = 13.581 min (DAD), 13.649 min (ELSD); LC/MS (ESI): m/z = 590.2 
(MH+) (Rt = 12.90 min, 100%); ESI: m/z = 590.1 (MH+) (Rt = 13.88 min, 100%); HPLC 
(preparative): Gradient (t (min), % B: (0, 3), (13, 44), (15, 98), (25, 98), Rt = 12.215 min; 
Empirical formula: C34H35N7O3, MW = 589.69 
Sequence: H-W-W(Me)-W-NH2 (3b) 
Yield: 4.5 mg, 27% 
HPLC (analytic): Rt = 13.896 min (DAD), 13.966 min (ELSD); LC/MS (ESI): m/z = 590.2 
(MH+) (Rt = 13.19 min, 100%); ESI: m/z = 590.1 (MH+) (Rt = 14.14 min, 100%); HPLC 
(preparative): Gradient (t (min), % B: (0, 3), (13, 44), (15, 98), (25, 98), Rt = 12.505 min; 
Empirical formula: C34H35N7O3, MW = 589.69 
Sequence: H-nW-nH-nF-NH2 (4a)  
Yield: 1.5 mg, 25% 
HPLC (analytic): Rt = 10.125 min (DAD), 10.256 min (ELSD); LC/MS (ESI): m/z = 530.1 
(MH+) (Rt = 9.78 min, 100%); ESI: m/z = 285.9 (M+2H)2+ + MeCN (Rt = 4.17 min, 100%), 
530.1 (MH+)(58%); HPLC (preparative): Gradient (t (min), % B: (0, 3), (12, 41), (15, 98), 
(25, 98), Rt = 8.32 min; Empirical formula: C29H35N7O3, MW = 529.63 
Sequence: Ac-nW-nH-nF-NH2 (4b) 
Yield: 1.0 mg, 5% 
HPLC (analytic): Rt =12.623 min (DAD), 12.709 min (ELSD); LC/MS (ESI): 
m/z = 572.2989 (MH+) (Rt = 9.493 min, 100%); ESI: m/z = 572.2 (MH+) (Rt = 4.94 min, 
100%); HPLC (preparative): Gradient (t (min), % B: ((0, 3), (15, 50), (17, 98), (25, 98), 
Rt = 11.172 min; Empirical formula: C31H37N7O4, MW = 571.67 
Sequence: H-nW-nH-nW-NH2 (5a) 
Yield: 1.5 mg, 10% 
HPLC (analytic): Rt = 10.118 min (DAD), 10.218 min (ELSD); LC/MS (ESI): 
m/z = 569.1 (MH+) (Rt = 10.0 min, 100%); ESI: m/z = 305.4 (M+2H)2+ + MeCN 
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(Rt = 4.20 min, 100%), 569.1 (MH+)(74%); HPLC (preparative): Gradient (t (min), 
%B: (0, 3), (12, 41), (15, 98), (25, 98), Rt = 8.360 min; Empirical formula: C31H36N8O3, 
MW = 568.67 
Sequence: Ac-nW-nH-nW-NH2 (5b) 
Yield: 0.6 mg, 4% 
HPLC (analytic): Rt = 12.722 min (DAD), 12.797 min (ELSD); LC/MS (ESI): 
m/z = 611.3098 (MH+) (Rt = 9.545 min, 100%); ESI: m/z = 611.2 (MH+) (Rt = 4.95 min, 
100%); HPLC (preparative): Gradient (t (min), % B: (0, 3), (15, 50), (17, 98), (25, 98), 
Rt = 11.178 min; Empirical formula: C33H38N8O4, MW = 610.71 
Sequence: H-nW-nW-nW-NH2 (6a) 
Yield: 0.3 mg, 2% 
HPLC (analytic): Rt = 15.104 min (DAD), 15.174 min (ELSD); LC/MS (ESI): m/z = 618.3 
(MH+) (Rt = 15.1 min, 100%); ESI: m/z = 618.3 (MH+) (Rt = 5.58 min, 100%); HPLC 
(preparative): Gradient (t (min), % B: (0, 3), (15, 50), (18, 98), (25, 98), Rt = 13.681 min; 
Empirical formula: C36H39N7O3, MW = 617.74 
Sequence: Ac-nW-nW-nW-NH2 (6b) 
Yield: 0.7 mg, 4% 
HPLC (analytic): Rt = 19.361 min (DAD), 19.427 min (ELSD); LC/MS (ESI): 
m/z = 660.3302 (MH+) (Rt = 16.225 min, 100%); ESI: m/z = 660.3 (MH+) (Rt = 6.65 min, 
100%); HPLC (preparative): Gradient (t (min), % B: (0, 3), (19, 63), (21, 98), (25, 98), 
Rt = 18.539 min; Empirical formula: C38H41N7O4, MW = 659.78 
Sequence: D-F-H-W-PEG (7) 
Yield: 14.1 mg, 45% 
HPLC (analytic): Rt = 12.175 min (DAD), 12.245 min (ELSD); LC/MS (ESI): 
m/z = 775.3409 (MH+) (Rt = 8.314 min, 100%); 
Empirical formula: C38H46N8O10, MW = 774.82 
Sequence: D-W-W-W-PEG (8) 
Yield: 11.2 mg, 32% 
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HPLC (analytic): Rt = 18.187 min (DAD), 18.258 min (ELSD); LC/MS (ESI): m/z = 863.5 
(MH+) (Rt = 18.04 min, 100%); 
Empirical formula: C45H50N8O10, MW = 862.93 
Sequence: D-W-H-W-PEG (9) 
Yield: 13.3 mg, 41% 
HPLC (analytic): Rt = 12.514 min (DAD), 12.590 min (ELSD); LC/MS (ESI): 
m/z = 814.4 (MH+) (Rt = 12.53 min, 100%); 
Empirical formula: C40H47N9O10, MW = 813.86 
Sequence: D-W-H-W-R-Y-P (10) 
Yield: 15.9 mg, 38% 
HPLC (analytic): Rt = 10.574 min (DAD), 10.650 min (ELSD); LC/MS (ESI): m/z = 521.4 
(M+2H+)2+ (Rt = 10.43 min, 100%); 
Empirical formula: C52H60N14O10, MW = 1041.12 
Sequence: D-H-W-H-F (11) 
Yield: 11.0 mg, 39% 
HPLC (analytic): Rt = 9.253 min (DAD), 9.341 min (ELSD); LC/MS (ESI): m/z = 382.5 
(M+2H+ + MeCN) (Rt = 9.04 min, 100%), 723.3 (MH+, 30%); ESI: m/z = 382.6 (M+2H+ + 
MeCN) (Rt = 3.82 min, 100%), 723.5 (MH+, 42%); HPLC (preparative): Gradient (t (min), 
% B: (0, 3), (9, 31), (12, 98), (22, 98), Rt = 7.277 min 
Empirical formula: C36H38N10O7, MW = 722.75 
Solid Phase Peptide Synthesis 
General procedure  
All peptides were prepared manually on 50 mg of Rink amide MBHA resin (loading 
0.56 mmol g-1) using Fmoc chemistry in BD discardit II syringes. Solvents and soluble 
reagents were removed by suction. The following side-chain protections were applied: 
tBu (Tyr), Boc (Trp), Mtt (His) and Pbf (Arg). Rink amide MBHA resin was weighed in 
a syringe equipped with a frit and swollen in DMF for 30 min. Afterwards, the 
corresponding Fmoc protected amino acid (5 eq) in NMP and the coupling reagents 
HOBt/TBTU/DIPEA (5:4.5:10 eq) in DMF were added. 
 
9. Melanoma inhibitory activity (MIA) protein inhibitors – Synthesis and biological testing 
 90
A single coupling procedure (45 min) was sufficient as the peptide sequences were 
short. Fmoc removal followed with piperidine in DMF (80:20, v/v) for 3 min plus 
10 min (20% base in DMF). After completion, the resin was washed with DMF, MeOH, 
DCM and Et2O (5 times each).  
The N-terminal acetylation is recommended for the preparation of protein fragments, 
as the N-acetyl group and the amide group better resemble the native situation and 
avoid the presence of positive and negative charges not present in a protein backbone. 
For N-terminal acetylation acetic anhydride (10 eq), DIPEA (10 eq) and DMF were 
added to the preswelled peptidyl-resin and the reaction was allowed to run for 30 min. 
Final cleavage of the peptides from the resin and simultaneous side-chain deprotection 
was achieved by treatment of the peptidyl resin with 1.5 mL of a TFA/TIS/water (90:5:5 
(v/v)) mixture for 3 h. The TFA solution was collected in a Falcon tube and reduced in 
volume to about 0.5 mL. The peptide was precipitated with cold Et2O and the 
suspension was centrifuged at -4 °C for 10 min. The supernatant was discarded and the 
precipitate was washed again with ice-cold ether. This procedure was repeated five 
times to remove most of the scavengers. Finally, the precipitate was dried under 
vacuum.  
General procedure for the synthesis of N-methylated Peptides 1-3 
Peptide chain elongation was performed by the general procedure described above. 
N-Methylation was achieved by the three-step procedure optimised by Biron et al.181 
Briefly, the free terminal amino group was protected with a solution of o-NBS-Cl (4 eq) 
and collidine (10 eq) in NMP. The mixture was shaken for 15 min at room temperature 
and the resin was washed with NMP (5×). Then, a solution of DBU (3 eq) in NMP was 
added to the resin bound o-NBS-protected peptides and shaken for 3 min. After 
addition of a solution of dimethylsulfate (10 eq) in NMP the reaction mixture was 
shaken for 2 min. The solution was drained and the resin was washed once with NMP. 
The N-methylation procedure was repeated once more and the resin was washed with 
NMP (5×). Mitsunobu conditions were applied to avoid the side chain N-methylation 
of His (Trt). The resin-bound o-NBS-protected peptides were treated with a solution of 
triphenylphosphine (5 eq) and MeOH (10 eq) in dry THF for 1 min. A solution of 
DEAD (5 eq) in dry THF was then added portionwise to the reaction mixture and 
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shaken for 10 min at room temperature. The resin was washed with NMP (5×). Finally, 
the o-NBS group was cleaved by shaking the resin bound Nα-methyl-Nα-o-NBS-
peptides with mercaptoethanol (10 eq) and DBU (5 eq) in NMP for 5 min. The 
deprotection procedure was repeated once more and the resin was washed with NMP 
(5×). The coupling of the next amino acid to the resin-bound Nα-methylamine free 
peptide was accomplished by shaking it with a solution of Fmoc-amino acid (3 eq), 
HATU (3 eq), HOAt (3 eq), DIEA (6 eq) in NMP for 2 h at room temperature. The 
coupling was repeated once more and the resin was washed with NMP (5×). Final 
cleavage of the peptides from the resin and simultaneous side-chain deprotection was 
achieved by treatment of the peptidyl resin with 1.5 mL of a TFA/TIS/water (90:5:5 
(v/v)) mixture for 3 h. 
General procedure for the synthesis of peptoids 4-6 
Peptoids were synthesised according to a solid-phase submonomer method published 
by Quintanar-Audelo et al.210  
Preswelling of the Rink Amide MBHA resin in DMF and deprotection of the Fmoc 
group was followed by acylation. A solution of chloroacetic acid (6 eq) and DIC (3 eq) 
in DMF was added to the resin, shaken for 1 h at room temperature and washed with 
DMF. For amination, a solution of amine (4 eq) and triethylamine (4 eq) in DMF was 
added to the resin and shaken for 4 h. Acylation and amination steps were successively 
repeated for chain assembly. N-terminal acetylation was achieved by shaking the resin 
with acetic anhydride (10 eq) and DIPEA (10 eq) in DMF for 30 min. The peptoids were 
cleaved by adding a mixture 2.0 mL of a TFA/DCM/anisole (49:49:2 (v/v)) solution for 
1 h. Alternatively, 2.0 mL of a TFA/DCE/water (49:49:2 (v/v)) mixture can be used. 
General procedure for the synthesis of cyclised peptides 7-11 
All peptides were prepared manually on 100 mg of Wang resin LL preloaded with 
Fmoc-Asp-OAlloc (loading 0.4 mmol g-1) using Fmoc chemistry in BD discardit II 
syringes. 
Preloading of Wang resin with Fmoc-Asp-OAlloc (according to Alcaro et al.)198 
1.5 g of a low loading Wang resin (0.44 mmol g-1) were preswelled in DMF for 30 min. 
DIC (153 μL, 124 mg, 1.5 eq) was added to a solution of Fmoc-Asp-OAll (784 mg, 3 eq) 
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in dry DCM (10 mL) and the mixture was stirred at 0 °C under N2 for 20 min. Then, the 
solution was concentrated and the residue dissolved in DMF (5 mL) (1). A second 
solution, containing DMAP (6.5 mg, 0.8 eq, 0.5 eq referred to DIC) in DMF (0.5 mL), 
was prepared (2). Both solutions (1+2) were added to the preswelled Wang resin and 
were shaken for 1 h. The resin was washed with DMF (3×2 min) and DCM (2×2 min). 
After endcapping with acetic anhydride (1.2 mL, 20 eq) and NMM (2.5 mL, 20 eq) in 
DCM (5 mL) for 1.5 h, the resin was washed with DCM (2×2 min), DMF (2×2 min) and 
DCM (2×2 min) and was dried under vacuum. The resin loading (0.4 mmol g-1) was 
determined from the Fmoc release monitored by UV absorption at 290 nm.  
Amino acids were assembled according to the standard Fmoc protocol. A double 
coupling step was performed for Fmoc-protected amino-PEG-acid spacer which were 
synthesized by Florian Schmidt.211  
Removal of allyl protecting group (according to Kates et al.)195 
The peptidyl resin was placed in a dry reaction tube and dried under high vacuum. 
A mixture of CHCl3/AcOH/NMM (37:2:1 (v/v), 4 mL) was added and degassed using 
4-5 freeze-pump-thaw cycles. After addition of Pd(PPh3)4 (3 eq), the reaction mixture 
was left to stand for 2 h in the dark with occasional gentle agitation. The resin was 
washed with DMF, a solution of 0.5% DIPEA in DMF (2×2 min), a solution of 0.5% 
sodium diethyldithiocarbamate in DMF (3×15 min), and finally with DMF, MeOH, 
DCM, and Et2O (5×2 mL each). The free carboxyl group was confirmed by the 
malachite green test.212 The Fmoc deprotected peptide was cyclised on the solid phase 
by a method published by Mollenkopf et al.201 A solution of DIPEA (6 eq) and T3P 
(6 eq) in ethyl acetate (50 % (w/w)) in DMF was added to the resin and shaken for 48 h 
at room temperature. After washing with DMF, MeOH, DCM, and Et2O (5×2 mL each), 
the peptide was cleaved from the resin with 1.5 mL of a TFA/TIS/water (90:5:5 (v/v)) 
mixture for 3 h. 
Coating of well plates with MIA-biotin, HTFP assay setup, and Protein analysis in 
vitro (Western Blotting) were performed according to literature.166 
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MIA protein is an important factor in the formation of metastases of the malignant 
melanoma. Highly potent MIA inhibitors would be a powerful tool in the treatment of 
this kind of skin cancer. Small peptidic molecules are known to inhibit the functional 
activity of MIA protein. However, administration of peptides and proteins requires an 
efficient protection against enzymatic degradation or extreme pH values. As 
therapeutic proteins are generally readily degraded, they only exhibit a low plasma 
concentration. To reduce the injection frequency, various drug delivery systems were 
investigated, including agents with covalently attached poly(ethylene glycol) (PEG) 
chains, a lipid implant, and injectable PEG hydrogels. 
 
 
 
 
 
 
 
 
 
 
 
All in vitro release studies were carried out by C. Ruß. The lipid implant was kindly 
produced by Angelika Berié, Department of Pharmaceutical Technology, University of 
Regensburg. The technology and precursors for poly(ethylene glycol) hydrogels were 
provided by the Department of Pharmaceutical Technology, University of Regensburg. 
All test assays of the biological activity were performed by Dr. Alexander Riechers, 
Institute of Molecular Pathology, Regensburg.  
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Introduction 
The challenging task to deliver therapeutic proteins efficiently to their biological target 
is impeded by their lack of stability, immunogenicity, and short half-life, resulting in a 
low bioavailability. We focused on two approaches to overcome these obstacles: the 
change of the molecular structure of the lead compounds and the change in 
formulation under retention of the original molecular structure. As we could see from 
our previous results (chapter 9), the modification of the chemical structure of the lead 
compound is often connected with the risk of losing or diminishing the functional 
activity at the target. For this reason, we also pursued the strategy to deliver the 
unchanged drug candidate by an appropriate drug delivery system. According to Jain, 
a drug delivery system is defined as “ a formulation or a device that enables the 
introduction of a therapeutic substance in the body and improves its efficacy and 
safety by controlling the rate, time, and place of release of drugs in the body.”171 
Furthermore, the drug delivery system protects the embedded drug from detrimental 
effects of the environment catalysing the degradation of the protein, like extreme pH 
values and high temperatures. By administering the drug via different anatomical 
routes, e.g. transdermal, nasal, pulmonary, oral, intravenous, and subcutaneous, some 
of these barriers can be circumvented. Furthermore, various formulations or devices 
can be applied such as tablets, emulsions, liposomes, polymers, implants or implanted 
pumps.171  
The goal of this study was to find a device that gradually releases the incorporated 
therapeutic agent. As a prerequisite, the device has to be small enough to be applicable 
in animal models, specifically in mice. To this end, various drug delivery systems were 
investigated, including agents with covalently attached poly(ethylene glycol) (PEG) 
chains (chapter 10.1), a lipid implant (chapter 10.2), and injectable PEG hydrogels 
(chapter 10.3). 
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10.1 Conjugation of poly(ethylene glycol) to melanoma inhibitory activity (MIA)  
inhibitors and biological evaluation 
Introduction 
One example, which will be illustrated in the following, is the covalent attachment of 
macromolecules to the therapeutic agent. Hence, the change of physico-chemical 
properties alters the pharmacodynamic and pharmacokinetic profile. The conjugation 
of poly(ethylene glycol) (PEG) to an active compound (PEGylation) is meanwhile a 
common method (in protein delivery) and has resulted in several clinically approved 
products.213  
In literature, many reviews summarised the effects of PEGylation, only a small 
selection of synthetic strategies of PEGylation is shown here.214-216 The most prominent 
features of PEG are now recapitulated. 
Linear and branched PEGs are accessible in a wide range of molecular weights. From 
the chemical point of view, PEGs are inexpensive, non-toxic, chemically stable, highly 
soluble in water and in many organic solvents and are available with a low 
polydispersity index (PDI); many reactions are established for derivatisation and they 
are approved for human use by the FDA (U.S. Food and Drug Administration).213  The 
most salient features of PEGylated drugs are a prolonged blood circulation time, an 
increase in stability against metabolic enzymes, and a reduced immunogenicity.217-219 
Attachment of PEG increases the size and the molecular weight of the original 
compound, and also its hydrophilicity. One effect is a decreased rate of (size-
dependent) kidney clearance. The PEG moiety also forms a kind of shell around the 
molecule, thus protecting it against uptake and clearance by the reticuloendothelial 
system (RES). This shell also masks antigenic sites and consequently the formation of 
neutralising antibodies is reduced. But this is only one side of the coin. PEGylation can 
change the conformation and electrostatic binding properties of the derivatised 
compound. Furthermore, the PEG shield often creates steric hindrance which results in 
a reduction of biological activity and binding affinity to the target structure. 
Nevertheless, many studies proved that the favourable features of this method often 
prevail over the disadvantages.217 
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The aim of this study was to evaluate if PEGylation of MIA inhibiting tripeptides 
would be a successful strategy to achieve higher plasma levels and to improve 
pharmacokinetics.  
Results and Discussion 
As simple conjugation with an activated PEG derivative to the MIA inhibitory peptides 
failed and synthesis - most reasonably by a liquid-phase peptide synthesis220 - from 
scratch is tedious and time-consuming, two tripeptides (WHF and WWW) were 
purchased with an N-terminal attached PEG chain of 2000 Da and subjected to the 
standard tests (see chapter 9.4).  
The HTFP assay showed that the PEG derivatives of the short peptide sequences were 
highly active: they effectively dissociate MIA protein from the surface which is inferred 
from the high change in polarisation (Figure 11A). It can be clearly seen that the tested 
compounds are superior (PEG-WWW) or similar (PEG-WHF) to the standard peptide 
AR71. Due to these promising results, the substances were directly tested in vitro by the 
Boyden Chamber Invasion Assay described below. 
Here, the invasion of cells of the melanoma cell line Mel Im was significantly reduced 
about 40% to 50% compared to untreated control cells after external treatment with 
MIA (Figure 11B). Pre-incubation of MIA with inhibitory compounds like AR71 or the 
PEGylated tripeptide completely neutralised the effect caused by MIA protein: the 
number of invaded cells was comparable to the number of the control cell line. 
Similarly, control lanes incubated only with the inhibitory compounds and without 
extra MIA protein (two columns on the right) confirmed that the drug candidates alone 
did not influence the migratory behaviour.  
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Figure 11 Results of A) the HTFP assay and B) Boyden chamber invasion assay of N-terminal 
PEGylated tripeptides.  
A) Displacement of MIA protein by the PEGylated compounds reduces the polarisation 
remarkably, implying a high inhibitory activity. 
B) The invasion of cells of the melanoma cell line Mel Im is significantly reduced by about 
40%to 50% compared to untreated control cells after external treatment with MIA. Pre-
incubation of MIA with inhibitory compounds like AR71 or the PEGylated tripeptide 
completely neutralised the effect caused by MIA protein: the number of invaded cells is 
comparable to the number of the control cells. 
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Boyden Chamber Invasion Assay 
This assay (Figure 12) measures the invasive or metastatic potential of tumor cells. To 
establish distant metastases, tumor cells must first cross the basement membrane, a 
thin extracellular matrix (ECM). Boyden Chambers consist of two compartments 
separated by a filter coated with matrigel. Matrigel is a commercialised cell culture 
matrix, primarily consisting of the ECM molecules laminin, collagen IV, and enactin.221 
Thus, the 3-D in vivo environment is mimicked and furthermore the matrix is 
considered as a reconstituted basement membrane preparation.221 Basically, melanoma 
cells are placed in the upper compartment of the Boyden chamber and the second 
chamber contains a chemoattractant. In this assay, only metastatic cells are able to 
penetrate through the matrix on the filter and attach to its surface, while non-
metastatic tumor cells cannot cross the barrier.222, 223 After a certain time of incubation, 
tumor cells are counted on the lower surface of the membrane. Albini et al. postulated 
that tumor cells first attach to the basement membrane via cell surface receptor, then 
secrete enzymes to degrade the adjacent membrane, and finally migrate into the target 
tissue in response to chemotactic stimuli.222 In 2003, Bosserhoff et al. used the Boyden 
chamber assay to reveal that MIA protein inhibits also the interaction of melanoma 
cells with matrigel. As a consequence, the tumor cells cannot attach to the matrix and 
thus, do not invade in this in vitro model.224 
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Frequently, PEGylation of proteins results in a loss of activity due to steric interference 
of the polymer chains with the biological target.218 Both in vitro assays clearly showed 
that PEGylation did not affect the biological activity of the tripeptides whose activity is 
comparable to the control peptide AR71. 
The good potency of the derivatives could be explained by a stabilising influence of 
PEG on the drug molecules: the polymer could mask sensitive amino acids and prevent 
the chemical degradation of the residues by oxidation or hydrolysis.225 Aromatic amino 
acids, like tryptophane and histidine, predominate in the short MIA inhibitors and are 
particularly prone to oxidation; oxidation can change the physico-chemical properties 
of a protein and cause aggregation or fragmentation.226 Aggregation of proteins is a 
common problem and associated with a decreased bioactivity, reduced solubility, and 
an increased immunogenicity.227 The high content of hydrophobic amino acids in the 
MIA inhibitors may also trigger aggregation, as the hydrophobic effect is considered to 
be the major driving force in this process.227 Conjugation of lipophilic drugs with 
hydrophilic polymers like PEG usually reduce the formation of aggregates and might 
overcome the above mentioned limitations. So far, the conducted experiments give 
 
upper compartment
lower compartment 
with chemoattractant
porous filter
matrigel
cell suspension
 
 
Figure 12 General principle of Boyden Chamber Invasion Assay which measures the invasive 
potential of tumor cells. Boyden Chambers consist of two compartments separated by a filter 
coated with matrigel. Melanoma cells are placed in the upper compartment of the Boyden 
chamber and the second chamber contains a chemoattractant. In this assay, only metastatic cells 
are able penetrate through the matrix on the filter and attach to its surface, while non-metastatic 
tumor cells cannot cross the barrier. After a certain time of incubation, tumor cells are counted 
on the lower surface of the membrane. 
 
10. Evaluation of different devices for the delivery of melanoma inhibitory activity (MIA) 
protein inhibitors 
 100
only information about how PEGylation influences the physical properties of the 
peptide. For a future application, detailed data about pharmacokinetics and in vivo 
half-life are essential and need to be collected.  
Conclusion 
Simple conjugation of a hydrophilic polymer to a drug prolongs the plasma circulation 
time and protects the therapeutic compound against metabolic degradation. The 
experiments showed that PEGylation of the potential drug candidates retained their 
affinity and resulted in a superior binding affinity and biological activity in 
comparison to the reference AR71. Due to their excellent in vitro performance, the 
PEGylated derivatives of MIA inhibitors were included in a patent held by Bosserhoff 
et al.165 In the future, in vivo studies are planned to obtain detailed pharmacokinetic 
information of the PEGylated peptides. 
Experimental 
General. The tripeptides PEG-WWW and PEG-WHF, PEGlyated at the N-terminus 
with an mPEG2000, were purchased from GL Brioche (Shanghai) Ltd., China. 
Coating of well plates with MIA-biotin, HTFP assay, conditions for cell lines and 
cell culture, and Boyden Chamber Invasion Assay were performed according to 
literature.166 
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10.2 Lipid implants as potential controlled release system for melanoma 
inhibitory activity (MIA) protein inhibitors 
Introduction 
Currently, daily i.v. injections of MIA inhibitory compounds are required to prevent or 
reduce the formation of metastases in mouse melanoma models. This frequency of 
application is caused by the short in vivo half-life of the peptidic inhibitors, and would 
be painful for the treated patients, resulting in a reduced compliance. One solution to 
this problem might be the implementation devices which release the drug at a 
predetermined rate. The goal of such sustained release formulations is to prolong the 
duration of action of the drug, to reduce the frequency of dosing, to minimise the 
fluctuations in plasma level, to improve drug utilisation, and to diminish adverse 
effects.171 Shortly, by releasing the drug constantly at the site of action, the therapy 
becomes more efficient, costs and the risk of toxic side effects can be reduced.228  
Lipid carriers are highly biocompatible as only naturally occurring materials are used 
as matrices, e.g. triglycerides, phospholipids, and cholesterol. Their main advantages 
are the simple manufacture of the devices by compression or moulding, the lower 
susceptibility to erosion phenomena, and their slower water uptake. Major drawbacks 
of these devices are drug degradation during preparation, especially when the 
commonly used high pressure homogenisation is applied. Due to crystallisation of the 
lipids in polymorphic forms, unpredictable release profiles and low drug loading 
might be the result.228 Upon degradation or erosion the drug is exposed to a constantly 
changing microenvironment which might damage the peptide or protein.228 Lipid 
based carriers for proteins and peptides were summarised by Rawat et al. in 2008.228 
Some examples for the formulations of physiological triglycerides as microparticles 
and cylindrical matrices are given in reference 229.  
The aim of this study was to find a drug carrier that releases the therapeutic agent 
continuously over 30 days and is also small enough to be applied in animal models. 
Ideally, 50 to 100 μg of peptide would be released per day.  
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Results and Discussion 
In our study, we used lipid implants as long-term release system based on the research 
of Koennings et al.230 They introduced an improved method for the preparation of lipid 
implants. To achieve a homogeneous protein distribution in the lipid cylinders, a PEG-
co-lyophilisation method was applied. The developed carriers contained 2 weight% of 
brain-derived neurotrophic factor (BDNF) and 60% of the total protein loading were 
continuously released over one month.  
To prove the feasibility of this system as sustained-release carrier, somatostatin was 
used as model substance. Somatostatin is a cyclic tetradecapeptide 
(AGCKNFFWKTFTSC) (Figure 13) with an internal disulfide bridge and a molecular 
weight of 1638 g/mol. It is a multi-functional peptide hormone regulating a great 
variety of biological processes, e.g. growth, metabolism, and development.231 In 
comparison, the dodecapeptide AR71 (Ac-FHWRYPLPLPGQ-NH2) (Figure 13) has a 
similar molecular weight of 1552 g/mol. Both peptides are mainly composed of 
hydrophobic and neutral, and a few basic amino acids. 
As the size of the implant needed to be small enough in order to be applicable in mice, 
the drug content in the carrier was raised to 10 weight% of the lipid matrix. At a release 
rate of 50 μg/day, the laboratory animals could be supplied with peptide over 36 days. 
This means that 1.8 mg of peptide were incorporated into the lipid matrix with a total 
weight of 18 mg and a diameter of 3 mm. To achieve higher loading, the implant was 
formulated without PEG. Furthermore, PEG is often applied as porogen. As a 
consequence, water intrudes into the interconnected pore network, facilitates 
 
Figure 13 Molecular structures of AR71 (left) and somatostatin (right). 
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dissolution and diffusion of the incorporated drug, finally resulting in a faster drug 
release.232 The implant was compressed and release behaviour was assessed at 37 °C.  
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Figure 14 In vitro release of somatostatin from glyceryl tripalmitate matrices incubated in 
phosphate buffer pH7.4 at 37 °C depicted as A) cumulative amount in %, and B) mg released 
per day. Most of the peptide is already released after 24 hours. 
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Our study showed that 83% of the peptide was released after 24 hours, as shown in 
Figure 14. After the initial burst, no significant amounts of peptide were found over the 
following weeks. This burst release effect is a common problem observed for controlled 
release systems. Thereby, a large amount of drug is immediately released upon 
placement in the release medium before the release profile reaches a stable profile.233 
Generally, to release drugs in aqueous medium, they need first to be dissolved and 
then diffuse through the porous structures of the matrix into the solution. The high 
initial release can be explained by a heterogeneous drug distribution in the matrix, 
either caused by the manufacturing method or due to the material properties. If the 
protein is mostly enriched in the surface, especially in the case of high drug loading, 
release will be extremely fast. An increased porosity of the matrix would also support a 
faster diffusion of the drug through the cracks, channels, and pores. The high drug 
loading of the carrier might also contribute to the mentioned effects. 
Apart from a different formulation and higher loading, the embedded drugs differ in 
molecular weight by one order of magnitude: BDNF has a molecular weight of 
13.6 kDa and somatostatin of 1.6 kDa. Diffusion of the smaller somatostatin may be less 
restricted by the matrix, resulting in the high initial burst.  
Conclusion 
Biologically occurring and biocompatible triglycerides are interesting materials for 
sustained release formulations. A new formulation of a lipid implant was developed as 
a potential carrier and reservoir for MIA inhibitors. An in vitro release study revealed 
that a small lipid implant, which was loaded with a model compound, released the 
drug almost completely after 24 hours. For this reason, this carrier will not be 
optimised and the focus will be laid on systems that fulfil the requirement of a 
controlled long-term release.  
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Experimental 
General. All chemicals were purchased from Aldrich, Fluka or Acros and used without 
further purification. Glyceryl tripalmitate (Dyanasan®116) was a gift from Sasol 
(Witten, Germany). Somatostatin Curamed ® ampoules containing 3 mg 
somatostatinacetate were from CuraMEDPharma GmbH. 
Preparation method of lipid microparticles  
3 mg of protein were dissolved in 1 mL of double-distilled water. After freezing in 
liquid nitrogen, the mixture was lyophilized at 6 °C and 0.12 mbar for 30 hours in a 
benchtop freeze-dryer (Beta 2-16 with LMC-2 system control, Christ, Osterode, 
Germany). When vacuum was removed, 1.5 mL THF were immediately added to the 
lyophilisate, resulting in a suspension of solid protein particles. Glyceryl tripalmitate 
(Dynasan 114®, 27 mg) was dissolved in the suspension with the help of sonication for 
5 seconds. Afterwards, the mixture was again frozen in liquid nitrogen.  
The organic solvent was removed from the frozen formulation under a vacuum of 
6×10-3 mbar and cooling (two stage High vacuum Pump E2M5, Edwards, Crawley, 
UK). The resulting dry powder was ground in an agate mortar.  
For all formulations, cylindrical matrices of 3 mm diameter, 5 mm height and 18 mg 
weight were prepared form the protein-loaded lipid powder by manual compression 
in a custom-designed compression tool made of hardened steel. Compression force 
was controlled at 560 N for 10 seconds by a Perkin-Elmer hydraulic press (Perkin-
Elmer, Ueberlingen, Germany). Matrices were weighed on an analytical balance to 
determine their exact weight prior to release studies. 
In vitro protein release behaviour 
All vials were treated with Sigmacote® prior to use to prevent adsorption of protein. 
The matrix was incubated in 0.5 mL of the release medium (50 mM phosphate buffer 
pH 7.4) in a water bath at 37 °C. Buffer was replaced completely after each sampling 
interval, the samples stored at -20 °C and thawed before analysis.  
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Determination of drug release via HPLC measurements 
The amount of somatostatin released at 37 °C was determined using the following 
HPLC method.  
Column: Supelcosil LC318, Shimadzu LC-10AT autosampler, SIL-10 AD autoinjector, 
FCV-10AL pump, CTO-10ASvp oven, SCL-10Avp controller, RF-10Axl fluorescence 
detector, SPC 10Avp UV detector; Software: Class VP, Version 6.12, Shimadzu; 
Column temperature: 35 °C; Solvent A: water: MeCN = 90 : 10 + 0.1% TFA; solvent B: 
H2O: MeCN = 10 : 90 + 0.1% TFA; gradient: from 15% B to 50% B within 20 min. Flow 
rate: 1 mL/min, injection volume: 50 μL; UV detection at 210 and 280 nm, fluorescence 
detection λex= 280 nm, λem= 356 nm. The retention time of somatostatin under these 
conditions was approximately 12.3 min. Peptide solutions of known concentrations 
(0.1 – 1.0 μg/mL) were used to generate calibration curves.  
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10.3 Poly(ethylene glycol) based hydrogels for sustained delivery of melanoma 
inhibitory activity (MIA) protein inhibitors 
Introduction 
The rapid development of biotechnology entailed the discovery of a magnitude of 
potential protein drugs. Biopharmaceuticals are a rapidly growing field in 
pharmaceutical industry; currently, more than 25% of all substances are produced by 
biotechnological methods.234 Meanwhile, a considerable number of newly developed 
biotechnology drugs are proteins or peptides. However, the successful delivery of 
therapeutic proteins is still a challenge for the .pharmaceutical scientist.235 Application 
of suitable drug delivery systems would result in optimised pharmacokinetics, 
reduction of degradation, avoidance of detrimental systemic side effects, increase of 
bioavailability and reduction of the frequency of injection. A commonly investigated 
method in protein delivery is to entrap or encapsulate the therapeutic agents in 
polymeric carriers.235  
Hydrogels are highly biocompatible and widely used in the biomedical sector.236 They 
consist of physically or covalently cross-linked hydrophilic polymers which swell in 
aqueous media due to the uptake of water, but are not dissolved by the medium.237, 238 
Their high water content and soft consistency resembles the native extracellular matrix 
resulting in high biocompatibility.238 Drugs can be embedded in the gel matrix and 
their release rate is mostly diffusion controlled.237, 238 However, the applicability of 
hydrogels in sustained release systems is still limited: incorporated compounds are 
rapidly released in a few hours to a few days due the high water content and the large 
pore size of most gels.238 To slow down the release rate, different strategies have been 
applied. First, the microstructure of the hydrogel can be altered to increase the 
diffusive barrier. This can be achieved by using interpenetrating polymer networks.238 
To do this, a second second hydrogel network is polymerised within a pre-polymerised 
hydrogel. Thus not only the mechanical properties can be changed, but also mesh size 
or pH responsitivity of the hydrogel can be tuned. Other methods to increase the 
diffusive barrier include the grafting a second polymer film onto the surface or 
entrapping microparticles into the gels to form composite hydrogels.238 In addition, the 
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interactions between drug and the hydrogel network can be strengthened by 
electrostatic interactions or by covalent conjugation (the polymer-drug bond is 
subsequently cleaved chemically or enzymatically).238  
The goal of this study was to design a drug reservoir based on PEG hydrogels that 
releases peptidic MIA inhibitor AR60I constantly over a predetermined time.  
Results and Discussion 
The high biocompatibility of the PEG hydrogels make them an interesting biomaterial 
with multiple applications, especially in biomedical science.239 The peptide AR60I, used 
here as a model compound for the release study, is a known MIA inhibitor with the 
sequence H-NSLLVSFQPPRAR-NH2 (Figure 15). 
 
In this study, hydrogels based on branched PEG succinimidyl carbonates and branched 
PEG amines, both with 10 kDa molecular weight, were used; gel formation occurs in 
situ upon chemical reaction of these macromers (Figure 16).240, 241  
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Figure 15 Chemical structure of peptidic MIA inhibitor AR60I. 
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Figure 16 Principle of the in situ forming of PEG hydrogels. The N-hydroxysuccinimide 
activated PEG (left) is conjugated to the second amine functionalised PEG component (right) 
under formation of an amide bond. Directly after mixing the precursor solutions, a highly 
elastic polymer network (bottom) is formed.  
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The drug was embedded into an in situ polymerising PEG hydrogel. The compounds 
were added to the gel forming polymer solutions and entrapped during the in situ 
cross-linking process. Usually, good nucleophiles like free amine groups of lysine 
residues can also react with the activated PEG monomer and are covalently bound to 
the polymer. Here, we do not expect such kind of interference with peptide AR60I as 
no nucleophilic residues are present. After incubation at 37 °C, the released peptide 
was determined by HPLC. Unfortunately, the HPLC measurements showed that the 
peptide was not stable in solution, indicated by numerous smaller peaks at similar 
retention time. Therefore, we evaluated the area under the curve of the UV signal at 
210 nm of a constantly recurring fragment (also confirmed by LC-MS) to acquire 
qualitative information. The diagram obtained by this method showed that the amount 
of released peptide decreases gradually (Figure 17). Apparently, the active compound 
is released within five days. These data must be interpreted with caution because it 
could not be determined if the total amount of the incorporated agent was released into 
solution or if the hydrogel still contained residual drug.  
 
 
0
1000
2000
3000
4000
5000
6000
0 2 4 6 8 10 12 14 16
Time (days)
A
U
C
 (m
A
U
*s
)
 
Figure 17 In vitro release of AR60I showing the cumulative area under the curve of a recurring 
fragment of the used peptide. The incorporated tridecapeptide is released over five days. 
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In general, hydrophilic compounds like peptides are suitable candidates to be 
embedded into a hydrophilic polymer network. Due to the high water content of the 
hydrogels, the peptide remains dissolved. However, the hydrogel has no significant 
diffusion barrier for the hydrophilic peptide resulting in a rapid release. As the drug 
release is diffusion controlled, prolonged drug release might be achieved by increasing 
of the hydrodynamic radius of the incorporated compound, reducing the mesh size or 
by increasing the polymer content of the hydrogel. 
Conclusion 
In summary, we applied biocompatible PEG hydrogels as drug delivery vehicles for 
small MIA protein inhibiting peptides and determined their drug release profile in 
vitro. The drug was encapsulated during the in situ cross-linking process. It was 
demonstrated that the used PEG hydrogel networks release the incorporated peptide 
within five days. However, the current results encourage us to further optimise the 
PEG carrier system in order to achieve sustained release in the future.  
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Experimental 
General. 4-armPEG10k-succinimidyl carbonate and of 4-armPEG10k-amine were 
synthesised according to Brandl et al.241Alginate Pronova UP LVM was purchased from 
Nova Matrix, Norway. AR60I was previously synthesised by solid phase synthesis. 
Preparation of PEG hydrogels loaded with peptide AR60I 
(H-NSLLVSFQPPRAR-NH2)  
For the release studies, accurately weighed amounts of the 4-armPEG10k-amine 
component were dissolved in peptide in aqueous solution and in 50 mM phosphate 
buffer, pH7.4 (control). Each of the solutions was added to a solution of 4-armPEG10k-
succinimidyl carbonate in 50 mM phosphate buffer. The stoichiometric ratio between 
succinimidyl carbonate and amino groups was balanced, and the overall polymer 
concentration was 5% (w/v) for all gels. After vortexing, 350 µL of the respective 
solutions were cast into cylindrical glass molds (7 mm inner diameter) and allowed to 
gel for 2 h. The gel cylinders were incubated in 3 mL of 50 mM phosphate buffer pH7.4 
(containing 0.1% NaN3) at 37 °C in a shaking water bath. Every day, samples of 1 mL 
were collected and replaced by the same volume of buffer.  
 
Determination of drug release via HPLC measurements 
The amount of released AR60I at 37 °C was determined using the following HPLC 
method.  
Column: Phenomenex Luna 3 um C18 (2) 100 A, 150 mm x 2.00 mm,  
Agilent 1100/1; G1312A Bin Pump, G1313A COLCOM, G131B DAD, G1379 
DEGASSER, G1321A FLD; software: ChemStation for LC 3D Systems Rev B.04.02 SP1; 
column temperature: 25 °C, FLD-A, ELS; UV detection at 210 and 220 nm, fluorescence 
detection λex= 280 nm, λem= 350 nm. Gradient: from 3% MeCN/H2O (0.0059% TFA) to 
98% MeCN/H2O (0.0059% TFA) within 30 min. Flow rate: 0.3 mL/min, injection 
volume: 30 μL. The retention time of AR60I under these conditions was approximately 
10.2 min. 
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11. Summary 
Aggressive growth accompanied by rapid metastasis makes the malignant melanoma a 
kind of cancer with a low rate of survival in an advanced stage. The melanoma 
inhibitory activity (MIA) protein reduces the cell contacts to the extracellular matrix 
and facilitates metastasis. Remarkably, MIA protein is exclusively expressed in 
malignant melanoma cells and chondrocytes. In comparison to other chemotherapeutic 
agents, anti metastatic agents (substances which inhibit the functional activity of MIA 
protein) would thus prevent the spreading of these cells and reduce the side effects of 
systemic chemotherapy dramatically. MIA protein is functionally active after 
formation of dimers. Small compounds which prevent this assembly would be very 
interesting drugs in the treatment of cancer. Short peptides consisting of three to 
eighteen amino acids were assessed in a screening process to inhibit the dimerisation of 
MIA protein in vitro and in vivo. The major drawback of proteins and peptides as drugs 
is their poor in vivo stability and the resulting low plasma concentration which is often 
below the effective dose. Currently, the poor pharmacokinetic properties of proteins 
often require daily injections which entail high costs and are a burden to the treated 
patients. Therefore, the aim of this thesis was to increase the in vivo stability of MIA 
inhibiting peptides and thus to achieve adequate drug levels in plasma. 
It was attempted to achieve this goal by simple modifications of the molecular 
structure of the known inhibitors, with the focus on modifications of the peptide 
backbone. The synthesised peptide mimetics were methylated at the nitrogen atom of 
the amide bond of the peptide chain, transformed to N-substituted glycines (peptoids), 
or cyclised in a head-to-tail fashion. Subsequent in vitro tests (HTFP assay, Western 
Blot analysis) of the derivatives showed that their activity was significantly reduced in 
comparison to the original compounds. This was attributed to a conformational change 
of the mimics due to variations in the chemical structure. The results implicate that 
their conformation differs strongly from the bioactive conformation, thus reducing the 
potency. As the structural variation of lead compounds is often connected with the risk 
of losing activity, a second approach was pursued. By applying drug delivery systems 
the molecular structure can be retained. Furthermore, these devices should ideally 
release a drug selectively at the site of action over a predetermined period of time. 
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Consequently, a constant plasma concentration might be maintained leading to a 
reduced frequency of application and overall in an improved therapy.  
Covalent attachment of polymers like poly(ethylene glycol) is a convenient method to 
increase the circulation time by reducing the rate of renal and hepatic clearance and 
metabolic degradation of the drugs. PEGylation of small MIA inhibitors led to highly 
active compounds, as in vitro tests showed. Future experiments will have to elucidate 
their pharmacokinetic properties. 
Sustained release devices are also suitable alternatives to reduce the drug 
administration frequency. A new formulation of biocompatible triglyceride implants 
released the incorporated peptide almost completely within 24 hours which provided 
no improvement over the current application method. For this reason, highly 
biocompatible PEG hydrogels were applied as slow-releasing matrices. The 
applicability of hydrogels in sustained release systems is still limited as incorporated 
compounds are rapidly released. It was observed that the incorporated model peptide 
was released within five days from PEG hydrogels. 
In conclusion, first steps to increase the in vivo stability of MIA inhibitors by different 
approaches have been made within the scope of this thesis. Certainly, many 
experiments will still be necessary in order to obtain a marketable product for the 
treatment of malignant melanoma. First steps have been made in the challenging field 
of peptide delivery. The knowledge attained in this work contributes significantly to 
future work of optimising the molecular structure of the drug or the drug carrier 
system 
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12. Zusammenfassung 
Aggressives Wachstum mit schneller Metastasierung macht das maligne Melanom zu 
einer Krebsart mit einer sehr niedrigen Überlebensrate im fortgeschrittenen Stadium. 
Das Protein MIA ermöglicht es den Krebszellen sich aus der extrazellulären Matrix zu 
lösen und erleichtert so die Metastasenbildung. Das Besondere am MIA Protein ist, das 
es ausschließlich in malignen Melanomzellen und Chondrocyten exprimiert wird. 
Antimetastasische Wirkstoffe, die die Funktion des MIA Proteins unterbinden, würden 
somit nur die Verbreitung dieser Zellen verhindern und so Nebenwirkungen im 
Vergleich zu anderen Chemotherapeutika drastisch reduzieren.  
Das Melanoma Inhibitory Activity (MIA) Protein erfüllt erst dann seine biologische 
Funktion, wenn es Dimere gebildet hat. Einfache Verbindungen, die diese 
Dimerisierung verhindern bzw. die aktiven Dimere dissoziieren, wären deshalb sehr 
interessante Therapeutika. In einem Screening Verfahren wurden kurze Peptide mit 
drei bis achtzehn Aminosäuren entdeckt, die die Dimerbildung des MIA Proteins in 
vitro und in vivo inhibieren.  
Der große Nachteil von Proteinen und Peptiden als Wirkstoffe ist deren geringe in vivo 
Stabilität und die daraus resultierende niedrige Plasmakonzentration, oftmals 
unterhalb der wirksamen Dosis. Derzeit erfordern die schlechten pharmakologischen 
Eigenschaften von Proteinen und Peptiden regelmäßige Injektionen, die mit einem 
hohen Kostenaufwand und auch einer Belastung für die Patienten verbunden sind.  
Das Ziel dieser Arbeit war es deshalb, die in vivo Stabilität der MIA inhibierenden 
Peptide zu erhöhen und damit ausreichende Wirkstoffspiegel im Plasma zu erreichen. 
Zunächst sollte die dieses Ziel durch einfache Veränderungen der chemischen 
Struktur, speziell am Peptidrückgrat, der bekannten Inhibitoren bewirkt werden. Die 
synthetisierten Peptidmimetika wurden am Stickstoffatom der Amidbindung in der 
Peptidkette methyliert, zu N-substituierten Glycinen (Peptoide) umgewandelt oder zu 
einem Ring mit einer Kopf-Schwanz-Struktur verknüpft. In den nachfolgenden in vitro 
Funktionstests (HTFP assay, Western Blot Analyse) der Derivate zeigte sich, dass sich 
die biologische Aktivität durch Strukturänderungen, im Vergleich zu den 
Originalsequenzen deutlich verringert hatte. Dies wurde auf eine 
Konformationsänderung der Mimetika zurückgeführt, so dass deren Konformation 
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stark von der bioaktiven Konformation abweicht und somit zu einer Verringerung der 
Wirkung führt. 
Aus diesem Grund wurde eine zweite Strategie verfolgt bei der die ursprüngliche 
Molekülstruktur beibehalten werden kann. Indem der Wirkstoff gezielt am Wirkort 
und über einen festgelegten Zeitraum freigesetzt wird, kann die Häufigkeit der 
Anwendung reduziert werden und gleichzeitig konstante Plasmaspiegel und damit 
eine Verbesserung der Therapie erreicht werden. 
Eine dafür geeignete Methode ist die kovalente Anknüpfung von Polymeren wie 
Poly(ethylen glykol) (PEG). Durch PEGylierung kann die Zirkulationsdauer erhöht 
werden, indem die renale und hepatische Clearance und auch der metabolische Abbau 
der Wirkstoffe verringert wird. Wie in in vitro Tests gezeigt wurde, führte die 
PEGylierung von kleinen MIA Inhibitoren zu hochaktiven Verbindungen. Zukünftige 
Experimente werden sich mit der Aufklärung der pharmakinetischen Eigenschaften 
befassen. Sustained release Formulierungen sind ebenfalls geeignete Alternativen, um 
die Häufigkeit der Injektionen herabzusetzen. Eine neue Formulierung eines 
Implantats basierend auf biokompatiblen Triglyceriden setzte das eingebettete 
Modellpeptid fast vollständig innerhalb von 24 Stunden frei; im Vergleich zur 
bisherigen Anwendungsweise stellt diese Methode keine Verbesserung dar. Deshalb 
wurden biokompatible PEG Hydrogele als langsam freisetzende Matrices eingesetzt. 
Die Anwendbarkeit von Hydrogelen als sustained release Systeme ist immer noch 
begrenzt, da die eingeschlossenen Verbindungen schnell freigesetzt werden. Es wurde 
beobachtet, dass das eingebettete Modellpeptid innerhalb von fünf Tagen freigesetzt 
wurde. Zusammenfassend wurde im Rahmen dieser Arbeit erste Schritte gemacht, die 
in vivo Stabilität von MIA Inhibitoren durch verschiedenartige Ansätze zu erhöhen. 
Obwohl sicherlich noch viele Experimente notwenig sein werden, um ein marktfähiges 
Produkt für die Behandlung des malignen Melanoms zu bekommen, wurden mit 
dieser Arbeit grundlegende Erkenntnisse gewonnen, die zur Entwicklung eines 
verbesserten Wirkstoffes bzw. eines Wirkstoffträgersystems maßgeblich beitragen 
werden.  
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14. Abbreviations 
 
Ac  acetyl 
AcOH  acetic acid 
Ac2O  acetic anhydride 
AS  ammonium salt 
ATR  attenuated total reflectance 
BCIP  5-bromo-4-chloro-3-indolyl phosphate 
BDNF  brain-derived neurotrophic factor 
[Bmim] 1-butyl-3-methylimidazolium 
[BMmorf] 4-benzyl-4-methylmorpholinium 
Boc  t-butyloxycarbonyl 
bpy  2,2’-bipyridine 
BSA  bovine serum albumine 
c  speed of light 
Ch  choline 
ChCl  choline chloride 
cP  centiPoise 
Cp  molar heat capacity 
DAD  diode array detector 
DCM  dichloromethane 
DEAD  diethyl azodicarboxylate 
DES  deep eutectic solvent 
DIC  N,N'-diisopropylcarbodiimide 
DIPEA  diisopropylethylamine 
DMAP  dimethylaminopyridine 
DMEM dulbecco’s modified eagle medium 
DMF  dimethylformamid 
DMSO  dimethylsulfoxide 
DMU  1,3-dimethylurea 
DPBS  dulbecco’s phosphate buffered saline 
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ECM  extracellular matrix  
[Emim] 1-ethyl-3-methylimidazolium 
ELSD  evaporative light scattering detector 
Et2O  diethylether 
EtOAc  ethylacetate 
Eq  equivalent 
Eqn  equation 
EtOH  ethanol 
ESI  electronic spray ionisation 
FCS  fetal calf serum 
FDA  U.S. food and drug administration 
FLD  fluorescence detector 
Fmoc  fluorenylmethoxycarbonyl 
FT  fourier transformed 
GMF  5-(α-D-glucosyloxymethyl)furfural 
h  Planck’s constant 
HATU 2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate 
HBD hydrogen bond donor 
HBTU 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate 
HMF  5-hydroxymethylfurfural 
HOAt 1-hydroxy-7-azabenzotriazole 
HOBt  hydroxybenzotriazole 
HPLC  high performance liquid chromatography 
HTFP  heterogeneous transition metal-based fluorescence polarization 
IL  ionic liquid 
IR  infrared spectroscopy 
i.v.  intravenous  
J  coupling constant 
LC/MS  liquid chromatography/mass spectrometry 
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LSI/MS liquid secondary ion mass spectrometry 
MBHA 4-methylbenzhydrylamine 
Me  methyl 
MeCN  acetonitrile 
MeOH  methanol 
MIA  melanoma inhibitory activity 
MP  melting point 
MS  mass spectrometry 
Mtt  4-metyltrityl 
νmax  wave number of absorption maximum 
NA  Avogadro’s constant 
NBT  nitro blue tetrazolium 
NBS  nitrobenzenesulfonyl chloride 
NEt3  triethylamine 
NMM  N-methylmorpholine 
NMP  N-methyl-2-pyrrolidone 
NMR  nuclear magnetic resonance 
NOE  nuclear overhauser effect 
NOESY nuclear overhauser effect spectroscopy 
NR  nile red 
OAll  allyl ether 
Pbf  2,2,4,6,7- pentamethyldihydrobenzofuran-5-sulfonyl 
PBS  phosphate buffered saline 
PDI  polydispersity index 
PE  petroleum ether 
PEG  poly(ethylene glycol) 
PVDF  polyvinylidene fluoride 
p-TsOH para-toluene sulfonic acid 
ρ  density 
RES  reticuloendothelial system 
rt  room temperature 
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Rt  retention time 
SDS-PAGE sodium dodecylsulfate polyacrylamide gel electrophoresis 
σ  conductivity 
TBTU  O-(benzotriazole-1-yl)-N,N,N’,N’-tetramethyluronium tetrafluoroborate 
tBu  tert.-butyl 
Tf  freezing point/temperature 
Tg  glass transition temperature 
THF  tetrahydrofurane 
TIS  triisopropylsilane 
TFA  trifluoroacetic acid 
TLC  thin layer chromatography 
Tm  melting point/temperature 
TOF  time of flight 
UV  ultraviolet 
wt%  weight percent 
 
Amino acids 
A 
C 
D 
E 
F 
G 
H 
I 
K 
L 
Ala  
Cys 
Asp 
Glu 
Phe 
Gly 
His 
Ile 
Lys 
Leu 
Alanine 
Cysteine 
Aspartic acid 
Glutamic acid
Phenylalanine
Glycine 
Histidine 
Isoleucine 
Lysine 
Leucine 
Füllze Füllze M 
N 
P 
Q 
R 
S 
T 
V 
W 
Y 
Met
Asn
Pro 
Gln
Arg
Ser 
Thr 
Val 
Trp 
Tyr 
Methionine 
Asparagine 
Proline 
Glutamine 
Arginine 
Serine 
Threonine 
Valine 
Tryptophan 
Tyrosine 
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